Vi anbefaler at du alltid bruker siste versjon av nettleseren din.
Illustrasjon av et dokument
Ahus kreftforskningssenter

Publikasjoner

Her finner du fagfellevurderte publikasjoner fra Ahus kreftforskningssenter for valgt år. Oversikten viser forskning som spenner fra grunnforskning til forebygging, diagnostikk, behandling og oppfølging, med mål om bedre pasientbehandling.

  1. Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore N, Dunshee C, Zschaebitz S, Oldenburg J, Ye DW, Lin X, Kalac M, Laird AD, Kennedy D, Agarwal N. Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled phase 3 TALAPRO-2 trial. Lancet. 2025;406(10502):461–74. Journal Impact Factor: 88,5.

 

  1. Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Saad F, Dunshee C, Zschabitz S, Oldenburg J, Lin X, Healy CG, Kalac M, Kennedy D, Fizazi K. Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet. 2025;406(10502):447–60. Journal Impact Factor: 88,5.

 

  1. Martling A, Hed Myrberg I, Nilbert M, Gronberg H, Granath F, Eklund M, Oresland T, Iversen LH, Haapamaki C, Janson M, Westberg K, Segelman J, Ersson U, Prytz M, Angenete E, Bergstrom R, Mayrhofer M, Glimelius B, Lindberg J, Group AS. Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer. N Engl J Med. 2025;393(11):1051–64. Journal Impact Factor: 78,5.

 

  1. Omland T, Heck SL, Holte E, Lilleaasen AM, Gynnild MN, Fagerland MW, Vinje-Jakobsen V, Naes AL, Blix ES, Larsen AI, Geisler J, Gulati G, Wethal T. Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. Circulation. 2025;152(16):1136–45. Journal Impact Factor: 38,7.

 

  1. Matsubara N, Azad AA, Agarwal N, Saad F, De Giorgi U, Joung JY, Fong PCC, Zschäbitz S, Jones RJ, Oldenburg J, Shore N, Dunshee C, Carles J, Fay AP, Cislo P, Chang JE, Healy CG, Niyazov A, Fizazi K. First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised , double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet Oncol. 2025;26(4):470–80. Journal Impact Factor: 35,9.

 

  1. Fay AP, Fizazi K, Matsubara N, Azad AA, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschabitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Cislo P, Chang J, Healy CG, Niyazov A, Agarwal N. First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet Oncol. 2025;26(4):481–90. Journal Impact Factor: 35,9.

 

  1. Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon MT, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Clarke CS, Clarke N, de Bono JS, De Santis M, Duran I, Efstathiou E, Ekeke ON, El Nahas TIH, Emmett L, Fanti S, Fatiregun OA, Feng FY, Fong PCC, Fonteyne V, Fossati N, George DJ, Gleave ME, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman MS, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khauli RB, Kramer G, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Renard-Penna R, Ryan CJ, Saad F, Sade JP, Sandhu S, Sartor OA, Schaeffer E, Scher HI, Sharifi N, Skoneczna IA, Soule HR, Spratt DE, Srinivas S, Sternberg CN, Suzuki H, Taplin ME, Thellenberg-Karlsson C, Tilki D, Turkeri LN, Uemura H, Urun Y, Vale CL, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2025;87(2):157–216. Journal Impact Factor: 25,2.

 

  1. Galsky MD, Heijden MSV, Powles T, Claps M, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Ürün Y, Ye DW, Valderrama BP, Tomita Y, Jiang RY, Filian J, Wang LLY, Losio MV, Sonpavde G. Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial. Eur Urol. 2025;88(4). Journal Impact Factor: 25,2.

 

  1. Gronberg BH, Killingberg KT, Flotten O, Bjaanaes MM, Brustugun OT, Madebo T, Langer SW, Risumlund SL, Schytte T, Helbekkmo N, Neumann K, Yksnoy O, Engleson J, Fluge S, Naustdal T, Giske LE, Nyman J, Tsakonas G, Halvorsen TO. High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC: Final Survival Data, Long-Term Toxicity, and Relapse Patterns in a Randomized, Open-Label, Phase II Trial. J Thorac Oncol. 2025;20(8):1108–19. Journal Impact Factor: 20,8.

 

  1. Zanti M, O'Mahony DG, Parsons MT, Dorling L, Dennis J, Boddicker NJ, Chen W, Hu C, Naven M, Yiangou K, Ahearn TU, Ambrosone CB, Andrulis IL, Antoniou AC, Auer PL, Baynes C, Bodelon C, Bogdanova NV, Bojesen SE, Bolla MK, Brantley KD, Camp NJ, Campbell A, Castelao JE, Cessna MH, Chang-Claude J, Chen F, Chenevix-Trench G, Geisler J, Conroy DM, Czene K, De Nicolo A, Domchek SM, Dork T, Dunning AM, Eliassen AH, Evans DG, Fasching PA, Figueroa JD, Flyger H, Gago-Dominguez M, Garcia-Closas M, Glendon G, Gonzalez-Neira A, Grassmann F, Hadjisavvas A, Haiman CA, Hamann U, Hart SN, Hartman MBA, Ho WK, Hodge JM, Hoppe R, Howell SJ, Jakubowska A, Khusnutdinova EK, Ko YD, Kraft P, Kristensen VN, Lacey JV, Li J, Lim GH, Lindstrom S, Lophatananon A, Luccarini C, Mannermaa A, Martinez ME, Mavroudis D, Milne RL, Muir K, Nathanson KL, Nunez-Torres R, Obi N, Olson JE, Palmer JR, Panayiotidis MI, Patel AV, Pharoah PDP, Polley EC, Rashid MU, Ruddy KJ, Saloustros E, Sawyer EJ, Schmidt MK, Southey MC, Tan VKM, Teo SH, Teras LR, Torres D, Trentham-Dietz A, Truong T, Vachon CM, Wang Q, Weitzel JN, Yadav S, Yao S, Zirpoli GR, Cline MS, Devilee P, Tavtigian SV, Goldgar DE, Couch FJ, Easton DF, Spurdle AB, Michailidou K. Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification. Nature Communications. 2025;16(1) (no pagination). Journal Impact Factor: 15,7.

 

  1. Johansen SH, Wisloff T, Edvardsen E, Kollerud ST, Jensen JSS, Agwu G, Matsoukas K, Scott JM, Nilsen TS. Effects of Systemic Anticancer Treatment on Cardiorespiratory Fitness: A Systematic Review and Meta-Analysis. JACC CardioOncol. 2025;7(2):96–106. Journal Impact Factor: 13,4.

 

  1. Johansen SH, Saeter M, Sarvari SI, Reinertsen KV, Edvardsen E, Wisloff T, Scott JM, Grydeland M, Raastad T, Hallen J, Kiserud CE, Lie HC, Solberg PA, Haugaa KH, Jensen JSS, Vatningen LH, Thorsen L, Nilsen TS. Effects of Aerobic Exercise on Cardiorespiratory Fitness and Cardiovascular Risk Factors in Long-Term Breast Cancer Survivors: A Randomized Controlled Trial. JACC CardioOncol. 2025;7(4):414–26. Journal Impact Factor: 13,4.

 

  1. Askeland FB, Bugge VH, Rasmussen AM, Lysen A, Haukas E, Moksnes M, Eilertsen AL, Tsykunova G, Eiken BD, Leknes NM, Rolke J, Stavseth V, Samstad E, Hallstensen RF, Szatkowski D, Hansen AA, Nilsen AS, Slordahl TS, Abdollahi P, Schjesvold F. Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma. Blood Cancer J. 2025;15(1):214. Journal Impact Factor: 11,6.

 

  1. Kastora SL, Pantiora E, Hong YH, Veeramani M, Azim HJr, Chakrabarti R, Geisler J, Knoop A, Lambertini M, Linderholm B, Meattini I, Partridge AH, Vaz-Luis I, Vorburger D, Yongue G, Karakatsanis A, Valachis A. Safety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: A meta-analysis based expert panel discussion. Cancer Treat Rev. 2025;133:102880. Journal Impact Factor: 10,5.

 

  1. van Wilpe S, Taha T, Rothmann EC, Altshuler E, Park J, Ledet EM, Rothermundt CS, Bergman AM, Willemsen AECAB, Tsantoulis P, Oldenburg J, Bernard-Tessier A, Fizazi K, Bbrecht DGJR, Bruijnen CP, van der Hulle T, Antonarakis ES, Omlin A, Gronberg H, Armstrong AJ, Sartor O, Sena LA, Beltran H, Bono JSD, Mehra N. Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer. Eur Urol Oncol. 2025;8(4):1020–9. Journal Impact Factor: 9,3.

 

  1. Marra G, van Leenders G, David G, Oderda M, Aas K, Heidegger I, Zattoni F, Malkiewicz B, Sigle A, Mantica G, Rivas JG, Tsaur I, Soeterik TFW, Nicoletti R, Palagonia E, Mattei A, Afferi L, Raskin Y, Chiu P, Briganti A, Montorsi F, Gontero P, Gandaglia G. Assessment of the Reporting and Incidence of Prostate Cancer Unconventional Histologies in Tertiary Referral Institutions: An Under-reported but Exploding Phenomenon? Eur Urol Oncol. 2025;8(4):875–8. Journal Impact Factor: 9,3.

 

  1. Crippa A, De Laere B, Discacciati A, Larsson B, Persson M, Johansson S, D'Hondt S, Hjälm-Eriksson M, Pettersson L, Enbla G, Ullen A, Lumen N, Karlsson CT, Sandzen J, Jänes E, Ghysel C, Olsson M, Sautois B, Schatteman P, De Roock W, Van Bruwaene S, Erbiene I, Darras J, Everaert E, De Maeseneer D, Anden M, Strijbos M, Luyten D, Mortezavi A, Oldenburg J, Ost P, Lindberg J, Gronberg H, Eklun M, Investigators P. Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial. Eur Urol Oncol. 2025;8(6):1486–95. Journal Impact Factor: 9,3.

 

  1. Hektoen HH, Tsuruda KM, Brustugun OT, Neumann K, Andreassen BK. Real-world comparison of pembrolizumab alone and combined with chemotherapy in metastatic lung adenocarcinoma patients with PD-L1 expression >/=50. ESMO Open. 2025;10(5):105073. Journal Impact Factor: 8,3.

 

  1. Bjorkeli EB, Johannessen K, Geitung JT, Karlberg A, Eikenes L, Esmaeili M. Deep neural network modeling for brain tumor classification using magnetic resonance spectroscopic imaging. PLOS Digit Health. 2025;4(4):e0000784. Journal Impact Factor: 7,7.

 

  1. Hoppe R, Winter S, Lo WY, Michailidou K, Bolla MK, Keeman R, Wang Q, Dennis J, Lush M, Kalari KR, Goetz MP, Wang L, Cairns J, Weinshilboum R, Shepherd L, Chen BE, Haberle L, Ruebner M, Beckmann MW, He W, Larson NL, Armasu SM, Schroth W, Chowbay B, Khor CC, Abubakar M, Antoniou AC, Bruning T, Castelao JE, Chang-Claude J, Geisler J, Nbcs C, Dork T, Eccles DM, Figueroa JD, Gago-Dominguez M, Garcia-Saenz JA, Gundert M, Hack CC, Hamann U, Han S, Hooning MJ, Huebner H, Abctb I, John EM, Ko YD, Kristensen VN, Linn S, Margolin S, Mavroudis D, Nevanlinna H, Neven P, Obi N, Park-Simon TW, Pylkas K, Rashid MU, Romero A, Saloustros E, Sawyer EJ, Tapper WJ, Tomlinson I, Wendt C, Winqvist R, Dunning AM, Simard J, Hall P, Pharoah PDP, Schwab M, Couch FJ, Czene K, Fasching PA, Easton DF, Schmidt MK, Ingle JN, Brauch H. Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer. NPJ Breast Cancer. 2025;11(1):18. Journal Impact Factor: 7,6.

 

  1. Botteri E, Hjorth S, Conforti F, Bagnardi V, Andreassen BK, Stoer NC, Bhargava S, Ursin G, Gandini S, Sloan EK, Chang AS. Aprepitant use during chemotherapy and association with survival in women with early breast cancer. Jnci-J Natl Cancer I. 2025;117(11):2249–58. Journal Impact Factor: 7,2.

 

  1. Niemann CU, Dubois J, Nasserinejad K, da Cunha-Bang C, Kersting S, Enggaard L, Veldhuis GJ, Mous R, Mellink CHM, van der Kevie-Kersemaekers AF, Dobber JA, Poulsen CB, Razawy W, Hollestein R, Frederiksen H, Janssens A, Schjodt I, Dompeling EC, Ranti J, Brieghel C, Mattsson M, Bellido M, Tran HTT, Kater AP, Levin MD. Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial. Blood Adv. 2025;9(15):3665–75. Journal Impact Factor: 7,1.

 

  1. Borgbjerg J, Breen BS, Kristiansen CH, Larsen NE, Medrud L, Mikalone R, Muller S, Naujokaite G, Negard A, Nielsen TK, Salte IM, Frokjaer JB. Agreement between Routine-Dose and Lower-Dose CT with and without Deep Learning-based Denoising for Active Surveillance of Solid Small Renal Masses: A Multiobserver Study. Radiol Imaging Cancer. 2025;7(4):e240250. Journal Impact Factor: 6,3.

 

  1. Bakke KM, Bousquet PA, Meltzer S, Bjornetro T, Rise F, Wilkins AL, Redalen KR, Ree AH. Serum metabolite levels identify incipient metastatic progression of rectal cancer. Commun Med (Lond). 2025;5(1):142. Journal Impact Factor: 6,3.

 

  1. Yao Z, Fang K, Liu G, Bjoras M, Jin VX, Wang J. Integrated analysis of differential intra-chromosomal community interactions: A study of breast cancer. Artif Intell Med. 2025;167:103180. Journal Impact Factor: 6,2.

 

  1. Omran TA, Camacho JLS, Senthakumaran T, Gundersen G, Alte AK, Randen U, Tunsjo HS, Sæther PC, Bemanian V. Fusobacterium-associated molecular and immunological alterations in colorectal cancer: Insights from a Norwegian cohort. Front Immunol. 2025;16. Journal Impact Factor: 5,9.

 

  1. Skourti E, Seip K, Mensali N, Jabeen S, Juell S, Oynebråten I, Pettersen S, Engebraaten O, Corthay A, Inderberg EM, Dolznig H, Maelandsmo GM, Egeland EV, Prasmickaite L. Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer. Breast Cancer Res. 2025;27(1). Journal Impact Factor: 5,6.

 

  1. Qvigstad LF, Aas K, Tulipan A, Hole KH, Storas AH, Hammarstrom C, Ghiasvand R, Holmedal SH, Berge V. Clinical Trial Protocol for prePSMA: A Multicenter, Randomized, Noninferiority Trial of Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as Triage for Extended Pelvic Lymph Node Dissection in Patients Scheduled for Robot-assisted Laparoscopic Radical Prostatectomy. Eur Urol Focus. 2025;11(6):915–20. Journal Impact Factor: 5,6.

 

  1. Vistad I, Skorstad M, Berntsen S, Demmelmaier I, Bjorge L, van de Poll-franse LV, Lindemann K, Nilsen EB, Haug A, Bentzen AG, Bohlin T, Stokstad T, Brummer T, Liavaag A, Lomsdal S, Holstad AD, Hagen MC. Empowerment and quality of life in gynecological cancer survivors: Outcomes from a multicenter quasi-experimental cohort study from Norway (the LETSGO trial). Cancer-Am Cancer Soc. 2025;131(16). Journal Impact Factor: 5,1.

 

  1. Reikvam H, Rolfsnes MG, Rolsdorph L, Sandnes M, Selheim F, Hernandez-Valladares M, Bruserud O. Ferritin in Acute Myeloid Leukemia: Not Only a Marker of Inflammation and Iron Overload, but Also a Regulator of Cellular Iron Metabolism, Signaling and Communication. Int J Mol Sci. 2025;26(12):15. Journal Impact Factor: 4,9.

 

  1. Li L, Pan D, Ai RX, Zhou Y. Mitochondria-Associated Pathways in Cancer and Precancerous Conditions: Mechanistic Insights. Int J Mol Sci. 2025;26(17). Journal Impact Factor: 4,9.

 

  1. Haug AJ, Stoer N, Langseth H, Siafarikas F, Botteri E, Fortner RT, Lindemann K. Non-steroidal anti-inflammatory medication use and endometrial cancer survival: A population-based Norwegian cohort study. Int J Cancer. 2025;157(2):277–87. Journal Impact Factor: 4,7.

 

  1. Godoy LR, El-Zein M, Cools P, Padalko E, Verberckmoes B, Degomme O, Vermandere H, Arroyo Muhr LS, Stosic MS, Franco EL, Longatto-Filho A. E6/E7 Similarity to Human Papillomavirus Prototypes and Performance of HPV Testing by Cobas 4800 HPV Test and Anyplex II HPV HR. J Med Virol. 2025;97(11):e70668. Journal Impact Factor: 4,6.

 

  1. Sletten R, Slaaen M, Oldervoll LM, Kjesbu Skjellegrind H, Saltyte Benth J, Astrom L, Kirkevold O, Bergh S, Gronberg BH, Rostoft S, Bye A, Mork PJ, Berger Christiansen O. Physical Performance and Activity in Older Prostate Cancer Survivors in Comparison with Population-based Matched Controls. Eur Urol Open Sci. 2025;71:87–95. Journal Impact Factor: 4,5.

 

  1. Senthakumaran T, Tannaes TM, Moen AEF, Brackmann SA, Jahanlu D, Rounge TB, Bemanian V, Tunsjo HS. Detection of colorectal-cancer-associated bacterial taxa in fecal samples using next-generation sequencing and 19 newly established qPCR assays. Mol Oncol. 2025;19(2):412–29. Journal Impact Factor: 4,5.

 

  1. Iversen GT, Loeng M, Holth AL, Lonning PE, Geisler J, Knappskog S. Germline variants in wild-type melanoma prone families. Mol Oncol. 2025;19(5):1493–507. Journal Impact Factor: 4,5.

 

  1. Kjobli E, Haug ES, Salvesen O, Arstad C, Bergesen AK, Brennhovd B, Carlsen B, Gharib-Alhaug B, Gudbrandsdottir G, Juliebo-Jones P, Haugland JN, Karlsvik AK, Larsen M, Lilleaasen GM, Mûller S, Plathan ML, Roaldsen M, Roth I, Schwenke BLL, Wahlqvist R, Wessel N, Wibe A, Beisland C. "Modernized" en Bloc Radical Cystectomy Versus Standard Radical Cystectomy: A Nationwide Multi-Institutional Propensity Score Matched Analysis. Cancers. 2025;17(3). Journal Impact Factor: 4,4.

 

  1. Mecinaj A, Vinje-Jakobsen V, Ngo DTM, Sverdlov AL, Myhre PL. The SARAH trial: more evidence on the role of neurohormonal blockers in prevention of anthracycline-induced cardiotoxicity. Heart Fail Rev. 2025;30(3):627–31. Journal Impact Factor: 4,2.

 

  1. Johansen SH, Reinertsen KV, Wisloff T, Saeter M, Sarvari SI, Kiserud CE, Strandos N, Edvardsen E, Grydeland M, Nilsen TS, Thorsen L. Effects of aerobic exercise on late effects and quality of life in long-term breast cancer survivors: a randomized controlled trial. JNCI Cancer Spectr. 2025;9(6). Journal Impact Factor: 4,1.

 

  1. Fuglestad AJ, Bousquet PA, Kostner AH, Meltzer S, Kleist B, Ree AH, Rajab IM, Potempa LA, Fernandez-Botran R, Kersten C. Circulating Levels of the Proinflammatory Monomeric Isoform of C-Reactive Protein (mCRP) Correlate with Intra-Tumoral mCRP Abundance in Stage II-III Colon Cancer Patients. J Inflamm Res. 2025;18:7115–25. Journal Impact Factor: 4,1.

 

  1. Stosic MS, Costanzi JM, Ambur OH, Rounge TB. GENOMICON-Seq enables realistic simulation of amplicon and exome sequencing for low-frequency mutation detection. Sci. 2025;15(1):23003. Journal Impact Factor: 3,9.

 

  1. Solis-Ponce L, Stosic M, Curico G, Espetia S, Sanchez-Grandez H, Hassan SS, Basiletti J, Soreng K, Acuna-Barrios M, Huarca-Balbin L, Yaya-Rios M, Vilcarino-Zevallos G, Lopez R, Matos A, Ramal-Asayag C, Obregon G, Arroyo Muhr LS. Genotype distribution and molecular characterization of HPV in the Peruvian amazon: insights into prevalence, lineage diversity, and viral integration. Sci. 2025;15(1):32535. Journal Impact Factor: 3,9.

 

  1. Quist-Paulsen P, Horvei L, Dalgaard J, Moksnes M, Eilertsen AL, Paulson M, Azrakhsh NA, Majeed W, Wik HS. Improved outcomes in elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol-A prospective study. Br J Haematol. 2025;207(6):2434–40. Journal Impact Factor: 3,9.

 

  1. Patzke S, Cascione L, Melhus KB, Munz N, Arribas AJ, Gaudio E, Generalov R, Repetto-Llamazares AHV, Dahle J, Bertoni F. Comprehensive analysis of (177)Lu-lilotomab satetraxetan in lymphoma cell lines: Implications for precision radioimmunotherapy and combination schemes. Br J Haematol. 2025;207(5):1855–62. Journal Impact Factor: 3,9.

 

  1. Narimani S, Roth Hoff S, Daehli Kurz K, Gjesdal KI, Geisler J, Grovik E. Comparative analysis of deep learning architectures for breast region segmentation with a novel breast boundary proposal. Sci. 2025;15(1):8806. Journal Impact Factor: 3,9.

 

  1. Kissova M, Martinez Segarra J, Iveland TS, Vestvik M, Ravlo E, Wang W, Hagen L, Liabakk NB, Camara-Quilez M, Arano Barenys M, Solheim O, Hoff BH, Sundby E, Bjoras M, Slupphaug G, Visnes T, Brambilla A. RNaseH2 inhibition potentiates temozolomide response in patient derived glioblastoma cells. Sci. 2025;15(1):41486. Journal Impact Factor: 3,9.

 

  1. Vasic T, Stimec MB, Stimec BV, Kjaestad E, Ignjatovic D. Jejunal Lymphatic and Vascular Anatomy Defines Surgical Principles for Treatment of Jejunal Tumors. Dis Colon Rectum. 2025;68(5):553–61. Journal Impact Factor: 3,7.

 

  1. Samuelsson M, Edman K, Neziraj M, Ericsson A. Aiming for survival: a qualitative single case study of support for family members across the care process in outpatient colorectal cancer care. Bmc Cancer. 2025;25(1). Journal Impact Factor: 3,4.

 

  1. Potsakis S, Silvola JT, Grov EK. Hearing, smell, and cognitive function after cancer treatment. Bmc Cancer. 2025;25(1):1485. Journal Impact Factor: 3,4.

 

  1. Hatletvedt ND, Engebrethsen C, Geisler J, Geisler S, Aas T, Lonning PE, Gansmo LB, Knappskog S. The impact of functional MDM2-polymorphisms on neutrophil counts in breast cancer patients during neoadjuvant chemotherapy. BMC Cancer. 2025;25(1). Journal Impact Factor: 3,4.

 

  1. Arroyo Muhr LS, Eklund C, Lagheden C, Correa RM, Fellner MD, Picconi MA, Songur N, Gultekin M, Cuschieri K, Pretet JL, Lepiller Q, Baraquin A, Silling S, Soreng K, Stosic M, Presthus GK, Arbyn M, Peeters M, Gucht SV, Padalko E, Chin T, Kehoe K, Pereira AR, Redzic N, Vanden Broeck D, Molano M, Murray GL, Garland SM, Pinto LA, Wilkinson DE, Poljak M, Dillner J. The Human Papillomavirus (HPV) Laboratory e-Manual: A comprehensive guide for HPV testing and research. J Clin Virol. 2025;179:105834. Journal Impact Factor: 3,4.

 

  1. Svalastoga M, Larsen TL, Brekke J, Enden T, Froen H, Garresori H, Jacobsen EM, Porojnicu AC, Ree AH, Torfoss D, Velle EO, Wik HS, Ghanima W, Sandset PM, Dahm AEA. Effect of drug interactions with apixaban on clinical outcomes in cancer patients with venous thromboembolism. Front Oncol. 2025;15. Journal Impact Factor: 3,3.

 

  1. Schandiz H, Farkas L, Park D, Liu Y, Andersen SN, Sauer T, Geisler J. High Ki67 expression, HER2 overexpression, and low progesterone receptor levels in high-grade DCIS: significant associations with clinical practice implications. Front Oncol. 2025;15:1467664. Journal Impact Factor: 3,3.

 

  1. Narimani S, Hoff SR, Kurz KD, Gjesdal KI, Geisler J, Grovik E. Sustainable deep learning-based breast lesion segmentation: impact of breast region segmentation on performance. BMC Med. 2025;25(1):406. Journal Impact Factor: 3,2.

 

  1. Bjorkeli EB, Esmaeili M. RunicNet: Leveraging CNNs With Attention Mechanisms for Cervical Cancer Cell Classification. Biomed. 2025;16:11795972251351815. Journal Impact Factor: 3,1.

 

  1. Gravdahl E, Dale O, Benth JS, Steine S, Augestad KM, Fredheim OM. Pharmacokinetics of subcutaneous and intravenous bolus doses of morphine in palliative care cancer patients receiving infusion of morphine: A pharmacokinetic substudy of a randomized controlled trial. Br J Clin Pharmacol. 2025;91(12):3422–31. Journal Impact Factor: 3.

 

  1. Brems-Eskildsen AS, Kenholm J, Brixen AT, Ronlev JD, Stenbygaard L, Dano H, Grunnet M, Jakobsen EH, Neimann J, Langkjer ST, Geisler J. A direct comparison of classical oral Navelbine vs metronomic Navelbine in metastatic breast cancer: results from the Danish Breast Cancer Group's (DBCG) NAME-trial. Breast Cancer Res Tr. 2025;213(2):237–46. Journal Impact Factor: 3.

 

  1. Johnsen OF, Riis R, Meltzer S, Augestad KM. Increasing age, neural invasion, extramural vascular invasion, and short-course radiotherapy in locally advanced rectal cancer are associated with decreased tumor regression: a retrospective cohort study. Tech Coloproctol. 2025;29(1):152. Journal Impact Factor: 2,9.

 

  1. Cai L, Mao F, Huang X, Li D, Pan D, Hu Y, Xu H, Zeng X, Chen Q, Ai R, Zhou Y. The potential contribution of metal dyshomeostasis to the occurrence of oral leukoplakia-through abnormal immune function. Metallomics. 2025;17(12):08. Journal Impact Factor: 2,9.

 

  1. Vasic T, Stimec M, Stimec BV, Ignjatovic D. Lymphatic and vascular anatomy define surgical principles for bowel-sparing radical treatment of ileal tumors. Surg Endosc. 2025;39(4):2711–20. Journal Impact Factor: 2,7.

 

  1. Vasic T, Stimec M, Stimec BV, Edwin B, Ignjatovic D. Lymphatic and vascular anatomy define surgical principles for radical treatment of distal duodenal and proximal jejunal tumors. Surg Endosc. 2025;39(8):5421–9. Journal Impact Factor: 2,7.

 

  1. Rutegard M, Lindskold M, Jorgren F, Landerholm K, Matthiessen P, Forsmo HM, Park J, Rosenberg J, Schultz J, Seeberg LT, Segelman J, Buchwald P. SELective defunctioning Stoma Approach in low anterior resection for rectal cancer (SELSA): Protocol for a prospective study with a nested randomized clinical trial investigating stoma-free survival without major LARS following total mesorectal excision. Colorectal Dis. 2025;27(2):e70009. Journal Impact Factor: 2,7.

 

  1. Montaldo NP, Nilsen HL, Bordin DL. Targeting base excision repair in precision oncology. DNA Repair. 2025;149. Journal Impact Factor: 2,7.

 

  1. Verrill M, Lux MP, Gligorov J, Geisler J, Duchnowska R, Elsberger B, Martin M. Genomic tests to guide management of breast cancer in Europe: regulation, reimbursement, adoption, and challenges. Future Oncol. 2025;21(27):3573–83. Journal Impact Factor: 2,6.

 

  1. van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Chatta G, Urun Y, Ye D, He Z, Valderrama BP, Ku JH, Tomita Y, Filian J, Wang L, Purcea D, Patel MY, Nasroulah F, Galsky MD. Treatment of advanced urothelial cancer with nivolumab plus chemotherapy versus chemotherapy alone (CheckMate 901 study): a plain language summary. Future Oncol. 2025;21(6):605–16. Journal Impact Factor: 2,6.

 

  1. Puco K, Notland CS, Szulkin R, Jonasson C, Beisland C, Johannesen TB, Solli O, Oldenburg J, Heinrich D. Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data Study (RECON3). Cancer Manag Res. 2025;17:103–12. Journal Impact Factor: 2,6.

 

  1. Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschabitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 study. Future Oncol. 2025;21(6):637–52. Journal Impact Factor: 2,6.

 

  1. Andersen K, Tjonnfjord GE, Hestdalen ML, Spetalen S, Panagopoulos I. Complex Genetic Evolution and Treatment Challenges in Myeloid Neoplasms: A Case of Persistent t(2;3)(p15~23;q26)/MECOM Rearrangement, SF3B1 Mutation, and Transient TNIP1::PDGFRB Chimera. Cancer Genomics Proteomics. 2025;22(1):24–33. Journal Impact Factor: 2,6.

 

  1. Asphaug L, Akslen LA, Blix ES, Boge B, Borgen EF, Brekke MB, Falk RS, Geitvik GA, Gilje B, Gravdehaug B, Heie A, Janssen E, Kiserud CE, Kursetgjerde T, Langerod A, Lomo J, Mannsåker B, Mortensen E, Olsson P, Porojnicu AC, Raj SX, Roe OD, Russnes HEG, Skjerven HK, Songe-Moller S, Vestlid MA, Ohnstad HO, Naume B. Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives. Clin Breast Cancer. 2025;25(6):e721–e30. Journal Impact Factor: 2,5.

 

  1. Alsoe L, Brackmann SA, Lefol Y, Wennerstrom AB, Liu Y, Risques RA, Andersen SN, Nilsen HL. Colonic Mucosal Gene Expression Profile in Patients with Neoplastic Progression in Longstanding Ulcerative Colitis. Clin. 2025;18:215–32. Journal Impact Factor: 2,3.

 

  1. Viktil E, Hanekamp BA, Nesbakken A, Loberg EM, Sjo OH, Negard A, Dormagen JB, Schulz A. MRI of early rectal cancer; bisacodyl micro-enema increases submucosal width, reader confidence, and tumor conspicuity. Abdom Radiol. 2025;50(6):2401–13. Journal Impact Factor: 2,2.

 

  1. Valachis A, Grp DP, Geisler J, Tuxen MK, Karihtala P. Metastatic triple-negative breast cancer - current treatment strategies in the Nordics: a modified Delphi study. Acta Oncol. 2025;64:349–57. Journal Impact Factor: 2,2.

 

  1. Nilsson M, Storas AH, Johannesen TB, Gjelsvik YM, Aas K, Fosså SD, Myklebust TÅ. Adverse health outcomes for prostate cancer patients treated with radiotherapy combined with androgen-deprivation therapy: A population-based, controlled study, from Norway. Acta Oncol. 2025;64:1109–16. Journal Impact Factor: 2,2.

 

  1. Neumann K, Berg J, Ashraf H, Isaksson J, Aija K, Borg MH, Rasmussen TR. Adherence to guidelines for incidental pulmonary nodules: insights from a Nordic survey. Acta Oncol. 2025;64:22–6. Journal Impact Factor: 2,2.

 

  1. Khalife G, Waris J, Bodtger U, Isaksson J, Neumann K, Haroardóttir H, Andersén H, Jekunen A, Lovén M, Vasankari T, Nurmi-Rantala S, Torkki P. Comparative study of lung cancer care and survival outcomes across the Nordic countries. Acta Oncol. 2025;64:734–41. Journal Impact Factor: 2,2.

 

  1. Hundvin JA, Bornstein M, Negard A, Holmedal SH, Meltzer S, Ree AH, Pilskog S, Redalen KR. Low b-values in apparent diffusion coefficient calculations overestimate diffusion in rectal cancer. Acta Oncol. 2025;64:1430–6. Journal Impact Factor: 2,2.

 

  1. Wedde TB, Hagen MS, Vatne KM, Nilsen LB, Hellebust TP, Lilleby W. Patient-reported long-term sexual morbidity in prostate cancer survivors treated with external beam radiation therapy alone or combined with high-dose-rate brachytherapy. Scand J Urol. 2025;60:14–22. Journal Impact Factor: 2,1.

 

  1. Hannestad I, Myklebust TA, Fossa SD, Muller S, Aas K. Real-world implementation and guideline adherence at inclusion of active surveillance for men with prostate cancer: a population-based study from the Cancer Registry of Norway. Scand J Urol. 2025;60:218–25. Journal Impact Factor: 2,1.

 

  1. Rosok BI, Ahmad SH, Fretland ÅA, Ostergaard D, Edwin B, Brudvik KW, Yaqub S. Surgical resection of adrenal metastases: Single-center experience and narrative literature review with emphasis on colorectal metastases. Scand J Surg. 2025;114(2):142–6. Journal Impact Factor: 1,9.

 

  1. Maksimovic N, Neumann K, Aamodt H, Eggum R, Reier-Nilsen F, Wesche J, Stavem K. Robot-assisted thoracic surgery (RATS): learning curve and outcomes for 200 consecutive pulmonary lobectomies in a Norwegian hospital. J Thoracic Disease. 2025;17(8):5936–50. Journal Impact Factor: 1,9.

 

  1. Gravdahl E, Steine S, Benth JS, Augestad KM, Fredheim OM. Subcutaneous versus intravenous route switch from oral to parenteral morphine in patients with cancer: randomised controlled trial. BMJ Support Palliat Care. 2025. Journal Impact Factor: 1,9.

 

  1. Holte SS, Avaliani N, Hoff G, Kazaryan AM, Jaioun K, Lauzikas G, Schultz JK. Effect of psyllium husk on low anterior resection syndrome after rectal cancer surgery-a pilot prospective cohort study. Front Surg. 2025;12. Journal Impact Factor: 1,8.

 

  1. Auren-Mokleby M, Aasbo G, Fredheim OMS, Mengshoel AM, Solbraekke KN, Thoresen L. "It turned out right for both of us": A qualitative study about a preference for home death and actual place of death. Death Stud. 2025;49(7):887–96. Journal Impact Factor: 1,8.

 

  1. Nilsen JA, Juul FE, Egeland A, Tandberg P, Norvard E, Lund-Iversen T, Schultz JK, Kalager M, Frigstad SO. Colorectal ESD in a nordic community hospital: learning curves and clinical outcomes. Scandinavian Journal of Gastroenterology. 2025;60(11):1043–52. Journal Impact Factor: 1,7.

 

  1. Stormorken E, Dahm AEA. Daratumumab-EPOCH for transformed anaplastic multiple myeloma. Hematology, Transfusion and Cell Therapy. 2025;47(4) (no pagination). Journal Impact Factor: 1,6.

 

  1. Larsen BH, Gerwing J, Lundeby T, Gulbrandsen P, Forde R. More than an extra set of ears: A video-based analysis exploring the role of companions in routine oncology visits. J Psychosoc Oncol. 2025;43(5):682–703. Journal Impact Factor: 1,5.

 

  1. Bohn SH, Reinertsen KV, Kiserud CE, Loge JH, Fossa A, Skaali T, Blomhoff R, Oldervoll LM, Courneya KS, Raastad T, Nilsen TS, Wisloff T, Lie HC, Berge T, Edvardsen E, Fagerli UM, Fjerstad E, Gjerset GM, Haavik I, Henriksen HB, Rutkovskiy A, Sandberg G, Seland M, Slott M, Tjessem KH, Viktil L, Thorsen L. Effects of a Multidisciplinary Intervention on Fatigue in Lymphoma Survivors With Chronic Fatigue: Protocol for a Randomized Controlled Trial (REFUEL). JMIR Res Protoc. 2025;14:e69336. Journal Impact Factor: 1,5.

 

  1. Sadik M, Barrington SF, Ulén J, Enqvist O, Trägårdh E, Saboury B, Nielsen AL, Loft A, Gongora JLL, Urdaneta JL, Kumar R, van Essen M, Edenbrandt L. AI Improves Agreement and Reduces Time for Quantifying Metabolic Tumour Burden in Hodgkin Lymphoma. Hematol Rep. 2025;17(6). Journal Impact Factor: 1,2.

 

  1. Ignjatovic D, Bergamaschi R, Stimec B. The forgotten nodes: a narrative review. Ann Laparosc Endosc. 2025;10:9. Journal Impact Factor: 0,8.

 

  1. Akhtar SN, Gudbrandsdottir G, Aarsæther E, Carlsen B, Dimmen M, Hannestad I, Haug ES, Hopland OA, Karlsvik AK, Kjobli E, Müller S, Moen CA, Juliebo-Jones P, Beisland C. Presentation and survival for urachal cancer: Findings from a nationwide multicenter cohort study in Norway. Urologia J. 2025;92(4):595–602. Journal Impact Factor: 0,7.

 

  1. Gynnild MN, Vinje-Jakobsen V, Holtrop J, Hageman SHJ, Holte E, Gulati G, Heck SL, Dorresteijn JAN, Visseren FLJ, Fagerli UM, Raj S, Dalen H, Omland T, Wethal T. Prognostic Performance of a Modified HFA-ICOS Tool for Prediction of Cardiovascular Complications in Cancer Patients. Jacc-Adv. 2025;4(12).

 

  1. Fjortoft MO, Garred O, Lingjærde OC, Lande KT, Ottestad L, Bergheim IR, Naume B, Sahlberg KK, Borgen E, Borresen-Dale AL, Engebråten O, Fritzman B, Geisler J, Geitvik GA, Hofvind S, Kristensen VN, Kåresen R, Langerod A, Mælandsmo GM, Russnes HG, Sauer T, Skjerven HK, Schlichting E, Sorlie T, Lomo J, Lamont C, Myklebust JH, Russnes H, Huse K, Rye IH. Single-cell analysis reveals tumour size as a key driver of immune cell profile alterations in primary breast tumours and corresponding lymph nodes. Bjc Rep. 2025;3(1).

 

  1. Bjørkeli EB, Esmaeili M. Multi-task glioma segmentation and IDH mutation and 1p19q codeletion classification via a deep learning model on multimodal MRI. Meta-Radiology. 2025;3(2).

 

  1. Bakke KM, Bjornetro T, Bousquet PA, Sanabria AM, Meltzer S, Luders T, Troseid AS, Stang E, Negard A, Froyen EA, Lunder AK, Lyckander LG, Aass HCD, Redalen KR, Ree AH. Dissemination of Mitochondrial DNA Variants: Looking at the 'Bigger' Picture of the Tumour Microenvironment in Rectal Cancer Patients. J Extracell Biol. 2025;4(11):e70097.

 

 

  1. Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Oldenburg, J, et al. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2024;30(1):257-64. Journal Impact Factor: 58.7.
  2. De Laere B, Crippa A, Discacciati A, Larsson B, Persson M, Johansson S, Oldenburg, J, et al. Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial. Nat Med. 2024;30(11):3291-302. Journal Impact Factor: 58.7.
  3. Gulati G, Broberg AM, Offersen BV. The Nordic Cardio-Oncology Society: mission and future goals. Eur Heart J. 2024;45(21):1869-71. Journal Impact Factor: 38.1.
  4. Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Oldenburg, J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2024;86(2):164-82. Journal Impact Factor: 25.3.
  5. Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Oldenburg, J, et al. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2024. Journal Impact Factor: 25.3.
  6. Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Oldenburg, J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024;86(2):148-63. Journal Impact Factor: 25.3.
  7. Bjerner J, Bratt O, Aas K, Albertsen PC, Fossa SD, Kvale R, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium. Eur Urol. 2024;86(1):20-6. Journal Impact Factor: 25.3.
  8. Tocchetti CG, Farmakis D, Koop Y, Andres MS, Couch LS, Formisano L, Gulati G, et al. Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology. Eur J Heart Fail. 2024;26(10):2055-76. Journal Impact Factor: 16.9.
  9. Brun MK, Gehin JE, Bjorlykke KH, Warren DJ, Klaasen RA, Sexton J, Jorgensen KK, et al. Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomized, controlled NOR-DRUM trials. Lancet Rheumatol. 2024;6(4):e226-e36. Journal Impact Factor: 15.0.
  10. Istvan P, Birkeland E, Avershina E, Kvaerner AS, Bemanian V, Pardini B, et al. Exploring the gut DNA virome in fecal immunochemical test stool samples reveals associations with lifestyle in a large population-based study. Nat Commun. 2024;15(1):1791. Journal Impact Factor: 14.7.
  11. Mecinaj A, Gulati G, Ree AH, Gravdehaug B, Rosjo H, Steine K, et al. Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy-Related Cardiac Dysfunction. JACC CardioOncol. 2024;6(1):83-95. Journal Impact Factor: 13.6.
  12. Bai B, Wise JF, Vodak D, Nakken S, Sharma A, Blaker YN, et al. Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma. Blood Cancer J. 2024;14(1):147. Journal Impact Factor: 12.9.
  13. Shahrouzi P, Forouz F, Mathelier A, Kristensen VN, Duijf PHG. Copy number alterations: a catastrophic orchestration of the breast cancer genome. Trends Mol Med. 2024;30(8):750-64. Journal Impact Factor: 12.8.
  14. Maggadottir SM, Dueland S, Mensali N, Hamre H, Andresen PA, Myhre MR, et al. Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer. Mol Ther. 2024;32(6):2021-9. Journal Impact Factor: 12.1.
  15. Fonseca P, Cui W, Struyf N, Tong L, Chaurasiya A, Casagrande F, Gondor A, et al. A phenotypic screening approach to target p60AmotL2-expressing invasive cancer cells. J Exp Clin Cancer Res. 2024;43(1):107. Journal Impact Factor: 11.4.
  16. Schmiester L, Braso-Maristany F, Gonzalez-Farre B, Pascual T, Gavila J, Tekpli X, Geisler J, et al. Computational Model Predicts Patient Outcomes in Luminal B Breast Cancer Treated with Endocrine Therapy and CDK4/6 Inhibition. Clin Cancer Res. 2024;30(17):3779-87. Journal Impact Factor: 10.4.
  17. Skotheim RI, Bogaard M, Carm KT, Axcrona U, Axcrona K. Prostate cancer: Molecular aspects, consequences, and opportunities of the multifocal nature. Biochim. 2024;1879(2):189080. Journal Impact Factor: 9.7.
  18. Cestelli L, Johannessen A, Gulsvik A, Stavem K, Nielsen R. Risk Factors, Morbidity, and Mortality in Association With Preserved Ratio Impaired Spirometry and Restrictive Spirometric Pattern: Clinical Relevance of Preserved Ratio Impaired Spirometry and Restrictive Spirometric Pattern. Chest. 2024;27:27. Journal Impact Factor: 9.5.
  19. O'Brien RM, Meltzer S, Buckley CE, Heeran AB, Nugent TS, Donlon NE, et al. Complement is increased in treatment resistant rectal cancer and modulates radioresistance. Cancer Lett. 2024;604:217253. Journal Impact Factor: 9.1.
  20. Riis RN, Augestad KM. Author response to: Comment on: Beyond the transanal total mesorectal excision moratorium: local and distant recurrence among patients operated for low rectal tumors—5-year follow-up from a Norwegian University Hospital. Br J Surg. 2024;111(1):03. Journal Impact Factor: 8.7.
  21. Slevin F, Zattoni F, Checcucci E, Cumberbatch MGK, Nacchia A, Cornford P, Oldenburg J, et al. A Systematic Review of the Efficacy and Toxicity of Brachytherapy Boost Combined with External Beam Radiotherapy for Nonmetastatic Prostate Cancer. Eur Urol Oncol. 2024;7(4):677-96. Journal Impact Factor: 8.3.
  22. Lia K, Jorgensen RRK, B LW, Fluge O, Fagerli UM, Bersvendsen H, Bhargava S, et al. Overall survival and causes of death in elderly patients with Hodgkin lymphoma: a Norwegian population-based case-control study. Haematologica. 2024;109(5):1403-12. Journal Impact Factor: 8.2.
  23. Davidson AL, Michailidou K, Parsons MT, Fortuno C, Bolla MK, Wang Q, Geisler J, et al. Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset. American Journal of Human Genetics. 2024;111(9):2059-69. Journal Impact Factor: 8.1.
  24. Banipal GS, Stimec BV, Andersen SN, Edwin B, Nesgaard JM, Saltyte Benth J, et al. Are Metastatic Central Lymph Nodes (D3 volume) in right-sided Colon Cancer a Sign of Systemic Disease? A sub-group Analysis of an Ongoing Multicenter Trial. Ann Surg. 2024;279(4):648-56. Journal Impact Factor: 7.9.
  25. Azad AA, Fizazi K, Matsubara N, Saad F, De Giorgi U, Joung JY, Oldenburg J, et al. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study. Eur J Cancer. 2024;213:115078. Journal Impact Factor: 7.6.
  26. Slaaen M, Royset IM, Saltvedt I, Gronberg BH, Halsteinli V, Dohl O, ….., Saltyte Benth J. Geriatric assessment with management for older patients with cancer receiving radiotherapy: a cluster-randomized controlled pilot study. BMC Med. 2024;22(1):232. Journal Impact Factor: 7.1.
  27. Ohnstad HO, Blix ES, Akslen LA, Gilje B, Raj SX, Skjerven H, Geisler J, et al. Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1). ESMO open. 2024;9(6):103475. Journal Impact Factor: 7.1.
  28. Wang J, Yang M, Ali O, Dragland JS, Bjoras M, Farkas L. Predicting regulatory mutations and their target genes by new computational integrative analysis: A study of follicular lymphoma. Comput Biol Med. 2024;178:108787. Journal Impact Factor: 7.0.
  29. Cabrero-de Las Heras S, Hernandez-Yague X, Gonzalez A, Losa F, Soler G, Buges C, Ree AH, et al. Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment. Biomed Pharmacother. 2024;176:116857. Journal Impact Factor: 6.9.
  30. Costanzi JM, Stosic MS, Lovestad AH, Ambur OH, Rounge TB, Christiansen IK. Changes in intrahost genetic diversity according to lesion severity in longitudinal HPV16 samples. J Med Virol. 2024;96(5):e29641. Journal Impact Factor: 6.8.
  31. Ree AH, Hoye E, Esbensen Y, Beitnes AR, Negard A, Bernklev L, et al. Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade. Oncoimmunology. 2024;13(1):2372886. Journal Impact Factor: 6.5.
  32. Ree AH, Saltyte Benth J, Hamre HM, Kersten C, Hofsli E, Guren MG, et al. First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomized METIMMOX trial. Br J Cancer. 2024;130(12):1921-8. Journal Impact Factor: 6.4.
  33. Bogaard M, Stromme JM, Kidd SG, Johannessen B, Bakken AC, Lothe RA, Axcrona K, et al. GRIN3A: A biomarker associated with a cribriform pattern and poor prognosis in prostate cancer. Neoplasia. 2024;55:101023. Journal Impact Factor: 6.3.
  34. Tian Y, Lautrup S, Law PWN, Dinh ND, Fang EF, Chan WY. WRN loss accelerates abnormal adipocyte metabolism in Werner syndrome. Cell and Bioscience. 2024;14(1) (no pagination). Journal Impact Factor: 6.1.
  35. Sharma A, Debik J, Naume B, Ohnstad HO, Sahlber KK, Borgen E, Geisler J, et al. Comprehensive multi-omics analysis of breast cancer reveals distinct long-term prognostic subtypes. Oncogenesis. 2024;13(1) (no pagination). Journal Impact Factor: 5.9.
  36. Ovestad IT, Dalen I, Soreng K, Akbari S, Lapin M, Janssen EA, et al. Gene expression levels associated with impaired immune response and increased proliferation could serve as biomarkers for women following cervical cancer screening programs. Front. 2024;15:1507193. Journal Impact Factor: 5.7.
  37. Omran TA, Tunsjo HS, Jahanlu D, Brackmann SA, Bemanian V, Saether PC. Decoding immune-related gene signatures in colorectal neoplasia. Front. 2024;15:1407995. Journal Impact Factor: 5.7.
  38. Tinholt M, Tekpli X, Torland LA, Tahiri A, Geisler J, Kristensen V, et al. The breast cancer coagulome in the tumor microenvironment and its role in prognosis and treatment response to chemotherapy. J Thromb Haemost. 2024;22(5):1319-35. Journal Impact Factor: 5.5.
  39. Heetman JG, van der Hoeven EJRJ, Zattoni F, Kesch C, Shariat S, Dal Moro F, Aas K, et al. External validation of nomograms including MRI features for the prediction of side-specific extraprostatic extension. Prostate Cancer and Prostatic Diseases. 2024;27(3):492-9. Journal Impact Factor: 5.1.
  40. Torland LA, Lai X, Kumar S, Riis MH, Geisler J, Luders T, et al. Benign breast tumors may arise on different immunological backgrounds. Mol Oncol. 2024;18(10):2495-509. Journal Impact Factor: 5.0.
  41. Senthakumaran T, Tannaes TM, Moen AEF, Brackmann SA, Jahanlu D, Rounge TB, Bemanian V, et al. Detection of colorectal-cancer-associated bacterial taxa in fecal samples using next-generation sequencing and 19 newly established qPCR assays. Mol Oncol. 2024;06:06. Journal Impact Factor: 5.0.
  42. Hussaini P, Larsen TL, Ghanima W, Dahm AEA. Risk Factors for Bleeding in Cancer Patients Treated with Conventional Dose Followed by Low-Dose Apixaban for Venous Thromboembolism. Thromb Haemost. 2024;124(4):351-62. Journal Impact Factor: 5.0.
  43. Bugge NS, Grotta Vetvik K, Alstadhaug KB, Braaten T. Cumulative exposure to estrogen may increase the risk of migraine in women. Cephalalgia. 2024;44(1):3331024231225972. Journal Impact Factor: 5.0.
  44. Bucher-Johannessen C, Senthakumaran T, Avershina E, Birkeland E, Hoff G, Bemanian V, et al. Species-level verification of Phascolarctobacterium association with colorectal cancer. mSystems. 2024;9(10):e0073424. Journal Impact Factor: 5.0.
  45. Arriola E, Jaal J, Edvardsen A, Silvoniemi M, Araujo A, Vikstrom A, et al. Feasibility and User Experience of Digital Patient Monitoring for Real-World Patients With Lung or Breast Cancer. Oncologist. 2024;29(4):e561-e9. Journal Impact Factor: 4.8.
  46. Hajj-Boutros G, Faust A, Muscedere J, Kim P, Abumrad N, Chevalier S, Lautrup S, et al. Navigating the Landscape of Translational Geroscience in Canada: A Comprehensive Evaluation of Current Progress and Future Directions. J Gerontol Ser A-Biol Sci Med Sci. 2024;79(7):9. Journal Impact Factor: 4.3.
  47. Pretet JL, Arroyo Muhr LS, Cuschieri K, Fellner MD, Correa RM, Picconi MA, Søreng K, Christiansen IK, et al. Human papillomavirus negative high grade cervical lesions and cancers: Suggested guidance for HPV testing quality assurance. J Clin Virol. 2024;171:105657. Journal Impact Factor: 4.0.
  48. Bhargava S, Gjesvik J, Thy J, Larsen M, Hofvind S. Breast cancer-specific survival among immigrants and non-immigrants invited to BreastScreen Norway. J Migr Health. 2024;9:100222. Journal Impact Factor: 3.9.
  49. Omran TA, Madso IL, Saether PC, Bemanian V, Tunsjo HS. Selection of optimal extraction and RT-PCR protocols for stool RNA detection of colorectal cancer associated immune genes. Sci. 2024;14(1):27468. Journal Impact Factor: 3.8.
  50. Knuth F, Tohidinezhad F, Winter RM, Bakke KM, Negard A, Holmedal SH, et al. Quantitative MRI-based radiomics analysis identifies blood flow feature associated with overall survival for rectal cancer patients. Sci. 2024;14(1):258. Journal Impact Factor: 3.8.
  51. van den Elshout R, Ariens B, Blaauboer J, Meijer FJA, van der Kolk AG, Esmaeili M, et al. Quantification of perineural satellitosis in pretreatment glioblastoma with structural MRI and a diffusion tensor imaging template. Neurooncol Adv. 2024;6(1):vdad168. Journal Impact Factor: 3.7.
  52. Loffeler S, Bertilsson H, Muller C, Aas K, Haugnes HS, Aksnessaether B, et al. Protocol of a randomized, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P). BJU Int. 2024;133(6):680-9. Journal Impact Factor: 3.7.
  53. Albertsen PC, Bjerner LJ, Pasovic L, Muller S, Fossa S, Carlsson SV, Oldenburg J. Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge. BJU Int. 2024;133(1):104-11. Journal Impact Factor: 3.7.
  54. Hjermstad MJ, Pirnat A, Aass N, Andersen S, Astrup GL, Dajani O, Hamre H, et al. PALLiative care in ONcology (PALLiON): A cluster-randomized trial investigating the effect of palliative care on the use of anticancer treatment at the end of life. Palliat Med. 2024;38(2):229-39. Journal Impact Factor: 3.6.
  55. Wang F, Eikeland E, Reidunsdatter RJ, Hagen L, Engstrom MJ, Geisler J, et al. Quantification of multiple steroid hormones in serum and human breast cancer tissue by liquid chromatography-tandem mass spectrometry analysis. Front. 2024;14:1383104. Journal Impact Factor: 3.5.
  56. Schandiz H, Farkas L, Park D, Liu Y, Andersen SN, Geisler J, et al. Low progesterone receptor levels in high-grade DCIS correlate with HER2 upregulation and the presence of invasive components. Front. 2024;14:1347166. Journal Impact Factor: 3.5.
  57. Rao A, Stosic MS, Mohanty C, Suresh D, Wang AR, Lee DL, et al. Targeted inhibition of BET proteins in HPV16-positive head and neck squamous cell carcinoma reveals heterogeneous transcriptional responses. Front. 2024;14:1440836. Journal Impact Factor: 3.5.
  58. Malik YG, Benth JS, Hamre HM, Faerden AE, Schultz JK. Effect of radiotherapy on long-term quality of life in recurrence-free rectal cancer survivors (LaTE study): nationwide inverse probability of treatment-weighted registry-based cohort study and survey. BJS open. 2024;8(5):03. Journal Impact Factor: 3.4.
  59. Lara PN, Jr., Villanueva L, Ibanez C, Erman M, Lee JL, Heinrich D, et al. A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302). BMC Cancer. 2024;23(Suppl 1):1253. Journal Impact Factor: 3.4.
  60. Sletten R, Slaaen M, Oldervoll LM, Skjellegrind HK, Benth JS, Kirkevold O, et al. Physical Performance and Activity in Older Prostate Cancer Survivors in Comparison with Population-based Matched Controls. Eur Urol Open Sci. 2025;71:87-95. Journal Impact Factor: 3.2.
  61. Fossa SD, Holck Storas A, Aas K, Borge Johannesen T, Maria Gjelsvik Y, Myklebust TA. Pretreatment Patient-reported Overall Health: A Prognostic Factor for Early Overall Mortality After Primary Curative Treatment of Prostate Cancer. Eur Urol Open Sci. 2024;63:62-70. Journal Impact Factor: 3.2.
  62. Bernklev L, Nilsen JA, Augestad KM, Holme O, Pilonis ND. Management of non-curative endoscopic resection of T1 colon cancer. Baillieres Best Pract Res Clin Gastroenterol. 2024;68:101891. Journal Impact Factor: 3.2.
  63. Sletten R, Slaaen M, Oldervoll LM, Skjellegrind HK, Benth JS, Astrom L, et al. Self-reported health, function, and use of health care services in older prostate cancer survivors compared to matched controls: a cross-sectional study. J. 2024;17:17. Journal Impact Factor: 3.1.
  64. Chai Q, Yang Z, Liu X, An D, Du J, Ma X, Wu B, et al. Valuation of EQ-5D-5L health states from cancer patients' perspective: a feasibility study. Eur J Health Econ. 2024;25(6):915-24. Journal Impact Factor: 3.1.
  65. Valachis A, Biganzoli L, Christopoulou A, Fjermeros K, Fountzila E, Geisler J, et al. Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients. Fut Oncol. 2024;20(37):2937-48. Journal Impact Factor: 3.0.
  66. Fjermeros K, Ghannoum S, Geisler SB, Bhargava S, Tahiri A, Klajic J, et al. The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer. Fut Oncol. 2024;20(32):2457-66. Journal Impact Factor: 3.0.
  67. Chemtob A, Ignjatovic D, Stimec BV. Retrocolic Fascia—An Anatomical and Multidetector Computed Tomographic Angiography (MDCTA) Morphometric Analysis in Patients with Right Colon Cancer. Diagnostics (Basel). 2024;14(17):03. Journal Impact Factor: 3.0.
  68. Bertelsen BE, Almas B, Fjermeros K, Viste K, Geisler SB, Sauer T, et al. Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane. Breast Cancer Res Treat. 2024;206(2):347-58. Journal Impact Factor: 3.0.
  69. Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Oldenburg J, et al. Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer. Fut Oncol. 2024;20(29):2123-35. Journal Impact Factor: 3.0.
  70. Malik YG, Benth JS, Hamre HM, Faerden AE, Ignjatovic D, Schultz JK. Chemotherapy reduces long-term quality of life in recurrence-free colon cancer survivors (LaTE study)-a nationwide inverse probability of treatment-weighted registry-based cohort study and survey. Colorectal Dis. 2024;26(1):22-33. Journal Impact Factor: 2.9.
  71. Gravdahl E, Haugen DF, Fredheim OM. Use of peripherally inserted central venous catheters and midline catheters for palliative care in patients with cancer: a systematic review. Support Care Cancer. 2024;32(7):464. Journal Impact Factor: 2.8.
  72. Bohn S, Oldervoll L, Reinertsen K, Seland M, Fossa A, Kiserud C, Wisloff T, et al. The feasibility of a multidimensional intervention in lymphoma survivors with chronic fatigue. Support Care Cancer. 2024;32(1) (no pagination). Journal Impact Factor: 2.8.
  73. Storm M, Morken IM, Austin RC, Nordfonn O, Wathne HB, Urstad KH, Lurås H, et al. Evaluation of the nurse-assisted eHealth intervention 'eHealth@Hospital-2-Home' on self-care by patients with heart failure and colorectal cancer post-hospital discharge: protocol for a randomized controlled trial. BMC Health Serv Res. 2024;24(1):18. Journal Impact Factor: 2.7.
  74. Puco K, Fagereng GL, Brabrand S, Niehusmann P, Store Blix E, Samdal Steinskog ES, Meltzer S, Ree AH, et al. IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results. Acta Oncol. 2024;63:379-84. Journal Impact Factor: 2.7.
  75. Karihtala P, Schiza A, Fountzilas E, Geisler J, Meattini I, Risi E, et al. Clinical trials in older patients with cancer - typical challenges, possible solutions, and a paradigm of study design in breast cancer. Acta Oncol. 2024;63:441-7. Journal Impact Factor: 2.7.
  76. Iqbal N, Berstad P, Solbjor M, Diaz E, Czapka E, Hofvind S, Bhargava S. Access to colorectal cancer screening for Pakistani immigrants in Norway - a qualitative study. BMC Health Serv Res. 2024;24(1):799. Journal Impact Factor: 2.7.
  77. Gouliaev A, Berg J, Bibi R, Arshad A, Leira HO, Neumann K, et al. Multi-disciplinary team meetings for lung cancer in Norway and Denmark: results from national surveys and observations with MDT-MODe. Acta Oncol. 2024;63:678-84. Journal Impact Factor: 2.7.
  78. Nystad W, Hjellvik V, Larsen IK, Robsahm TE, Sund ER, Krokstad S, Wisloff T, et al. National health registries - a 'goldmine' for studying non-communicable disease occurrence in Norway - the NCDNOR project. Scand J Public Health. 2024;52(8):988-96. Journal Impact Factor: 2.6.
  79. Grindedal EM, Zucknick M, Stormorken A, Ronne E, Tandstad NM, Isaacs WB, Axcrona K, et al. Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome. Prostate. 2024;84(10):945-53. Journal Impact Factor: 2.6.
  80. Borgbjerg J, Rafdal H, Rasmussen GE, Johansen TJ, Svendsen ED, Graumann O. Improved Ice-Ball Visualization During CT-Guided Cryoablation of Renal Tumors Using Dual-Energy CT Virtual Monoenergetic and Electron Density Images. Journal of vascular and interventional radiology : JVIR. 2024;10. Journal Impact Factor: 2.6.
  81. Wasmuth HH, Faerden AE. The Norwegian Watch and Wait study: Norwait for rectal cancer. A report from a failed study—a word of caution. Updates Surg. 2024;76(5):1635-9. Journal Impact Factor: 2.4.
  82. van den Elshout R, Ariens B, Esmaeili M, Akkurt B, Mannil M, Meijer FJA, et al. Distinguishing glioblastoma progression from treatment-related changes using DTI directionality growth analysis. Neuroradiology. 2024;66(12):2143-51. Journal Impact Factor: 2.4.
  83. Viktil E, Hanekamp BA, Nesbakken A, Loberg EM, Sjo OH, Negard A, et al. MRI of early rectal cancer; bisacodyl micro-enema increases submucosal width, reader confidence, and tumor conspicuity. Abdom Radiol. 2024;08:08. Journal Impact Factor: 2.3.
  84. Theocharides A, Gisslinger H, De Stefano V, Accurso V, Iurlo A, Devos T, Dahm AEA, et al. Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study. Eur J Haematol. 2024;112(3):379-91. Journal Impact Factor: 2.3.
  85. Sefland O, Gullaksen SE, Omsland M, Reikvam H, Galteland E, Tran HTT, et al. Mass cytometric single cell immune profiles of peripheral blood from acute myeloid leukemia patients in complete remission with measurable residual disease. Cytometry B Clin Cytom. 2024;106(6):485-96. Journal Impact Factor: 2.3.
  86. Nilsson M, Aas K, Myklebust TA, Gjelsvik YM, Johannesen TB, Fossa SD. Adverse Health Outcomes 3 Years after Radical Prostatectomy Compared with Men in the General Population: A Study from the Cancer Registry of Norway. Clin Genitourin Cancer. 2024;22(6):102219. Journal Impact Factor: 2.3.
  87. Fredheim OMS, Klingenberg E, Lindahl AK. Prevalence of Triggers and Patient Harm Identified by Global Trigger Tool in Specialized Palliative Care. J Palliat Med. 2024;27(6):742-8. Journal Impact Factor: 2.2.
  88. Gachabayov M, Kajmolli A, Quintero L, Felsenreich DM, Popa DE, Ignjatovic D, et al. Inadvertent laparoscopic lavage of perforated colon cancer: a systematic review. Langenbecks Arch Surg. 2024;409(1):35. Journal Impact Factor: 2.1.
  89. Auren-Mokleby M, Aasbo G, Fredheim OMS, Mengshoel AM, Solbraekke KN, Thoresen L. "It turned out right for both of us": A qualitative study about a preference for home death and actual place of death. Death Stud. 2024:1-10. Journal Impact Factor: 2.1.
  90. Fredheim OM, Materstvedt LJ, Skulberg I, Magelssen M. Ought the level of sedation to be reduced during deep palliative sedation? A clinical and ethical analysis. BMJ support. 2024;13(e3):e984-e9. Journal Impact Factor: 2.0.
  91. Akman T, Arendt LM, Geisler J, Kristensen VN, Frigessi A, Kohn-Luque A. Modeling of Mouse Experiments Suggests that Optimal Anti-Hormonal Treatment for Breast Cancer is Diet-Dependent. Bull Math Biol. 2024;86(4):42. Journal Impact Factor: 2.0.
  92. Yao Z, Jin S, Zhou F, Wang J, Wang K, Zou X. A novel multiscale framework for delineating cancer evolution from subclonal compositions. J Theor Biol. 2024;582:111743. Journal Impact Factor: 1.9.
  93. Fredheim OMS, Torvund SK, Thoresen L, Magelssen M. How should respiratory depression and loss of airway patency be handled during initiation of palliative sedation? Acta Anaesthesiol Scand. 2024;68(5):675-80. Journal Impact Factor: 1.9.
  94. Sletten R, Berger Christiansen O, Oldervoll LM, Astrom L, Kjesbu Skjellegrind H, Saltyte Benth J, et al. The association between age and long-term quality of life after curative treatment for prostate cancer: a cross-sectional study. Scand J Urol. 2024;59:31-8. Journal Impact Factor: 1.4.
  95. Qvigstad LF, Eri LM, Lien MD, Fossa SD, Aas K, Berge V. Reduction of lower urinary tract symptoms in prostate cancer patients treated with robot-assisted laparoscopic prostatectomy. Scand J Urol. 2024;59:121-5. Journal Impact Factor: 1.4.
  96. Sadik M, Barrington SF, Tragardh E, Saboury B, Nielsen AL, Jakobsen AL, Gongora JLL, et al. Metabolic tumor volume in Hodgkin lymphoma—A comparison between manual and AI-based analysis. Clin Physiol Funct Imaging. 2024;44(3):220-7. Journal Impact Factor: 1.3.
  97. Tahri NB, Gravdehaug B, Bahrami N, Reitsma L. A woman in her fifties with a post-operative infection, generalized rash and organ failure. Tidsskr Nor Laegeforen. 2024;144(5):23. Journal Impact Factor: 1.2.
  98. Nilsen JA, Bernklev L, Bretthauer M, Kalager M, Jodal HC, Loberg M, et al. Surgical treatment of benign colorectal polyps 2008-21. Tidsskr Nor Laegeforen. 2024;144(10):10. Journal Impact Factor: 1.2.
  99. Viktil E, Hanekamp BA, Nesbakken A, Loberg EM, Sjo OH, Negard A, et al. Early rectal cancer: The diagnostic performance of MRI supplemented with a rectal micro-enema and a modified staging system to identify tumors eligible for local excision. Acta Radiol Open. 2024;13(5):20584601241241523. Journal Impact Factor: 0.9.
  100. Naimi S, Tetteh MA, Ashraf H, Johansen S. Evaluation of an in-use chest CT protocol in lung cancer screening - A single institutional study. Acta Radiol Open. 2024;13(7):20584601241256005. Journal Impact Factor: 0.9.
  101. Eide NA, Noer A, Jespersen H, Jebsen P, Geisler J. Delayed Distant Recurrence of a Uveal Melanoma 4 Decades after Enucleation. Case rep. 2024;17(1):1131-9. Journal Impact Factor: 0.9.
  102. Schandiz H, Nasser SNM, Ekeberg B, Pedersen MK, Leegaard TM, Sauer T. Human cystic echinococcosis detected in mesentery: A case report. SAGE Open Medical Case Reports. 2024;12(no pagination). Journal Impact Factor: 0.6.
  103. Brenne K, Staats K. Nurses' views on supporting young adults with terminally ill parents in Norwegian hospitals. Nordic Nursing Research. 2024;14(4):1-14. Journal Impact Factor: 0.2.
  104. Gustavsen EM, Norderval S, Dorum LM, Balto A, Heimdal R, Vonen B, et al. Socioeconomic and geographic variation in adjuvant chemotherapy among elderly patients with stage III colon cancer in Norway - a national register-based cohort study. Res Health Serv Reg. 2024;3(1):21. No Journal Impact Factor.
  105. Gustavsen EM, Haug ES, Haukland E, Heimdal R, Stensland E, Myklebust TA, et al. Geographic and socioeconomic variation in treatment of elderly prostate cancer patients in Norway - a national register-based study. Res Health Serv Reg. 2024;3(1):8. No Journal Impact Factor.

  1. Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D,Oldenburg, J,et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402(10398):291-303. Journal Impact Factor: 98,4.   

  

  1. van der Heijden MS,SonpavdeG, Powles T, Necchi A, Burotto M, Schenker M, Oldenburg, J, et al. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med. 2023;389(19):1778-89. Journal Impact Factor: 96,2.  

  

  1. HofvindS, Iqbal N, Thy JE,Mangerud G, Bhargava S, Zackrisson S, et al. Effect of invitation letter in language of origin on screening attendance: randomised controlled trial in BreastScreen Norway. Bmj. 2023;382:e075465. Journal Impact Factor: 93,6.  

  

  1. FizaziK, Azad AA,Matsubara N, Carles J, Fay AP, De Giorgi U, Oldenburg, J, et al. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2023:21. Journal Impact Factor: 58,7.  

  

  1. PatrikidouA, Cazzaniga W, Berney D,Boormans J, de Angst I, Di Nardo D, Oldenburg, J, et al. European Association of Urology Guidelines on Testicular Cancer: 2023 Update. Eur Urol. 2023;84(3):289-301. Journal Impact Factor: 25,3.  

  

  1. Bjerner L, Bratt O, Aas K, Albertsen PC,FossåSD, Kvåle R,...., Oldenburg, J, Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death—Results from the Norwegian Prostate Cancer Consortium. Eur Urol. 2023:1-7. Journal Impact Factor: 25,3. 

  

  1. Bamias A,StenzlA, Brown SL, Albiges L, Babjuk M, Birtle A, Oldenburg, J, et al. Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty. Eur Urol. 2023;84(4):381-9. Journal Impact Factor: 25,3.  

  

  1. Baldwin D, O'Dowd E,TietzovaI, Kerpel-Fronius A, Heuvelmans M, Snoeckx A, Asraf H, et al. Developing a Pan-European Technical Standard for a Comprehensive High-quality Lung Cancer CT Screening Program. An ERS Technical Standard. Eur Respir J. 2023;18:18. Journal Impact Factor: 16,6 (pending 17,0).  

  

  1. Hoye E,DagenborgVJ, Torgunrud A, Lund-Andersen C, Fretland AA, Lorenz S, Ree AH, et al. T cell receptor repertoire sequencing reveals chemotherapy-driven clonal expansion in colorectal liver metastases. GigaScience. 2023;12(no pagination). Journal Impact Factor: 11,8.  

  

  1. SolitanoV,Facciorusso A, McGovern DPB, Nguyen T, Colman RJ, Zou L, Jørgensen KK, et al. HLA-DQA1 05 Genotype and Immunogenicity to Tumor Necrosis Factor-alpha Antagonists: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023;21(12):3019-29.e5. Journal Impact Factor: 11,6.  

  

  1. NikolaienkoO, Eikesdal HP,Ognedal E, Gilje B, Lundgren S, Blix ES, Geisler J, Geisler S, et al. Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development. Genome Med. 2023;15(1):104. Journal Impact Factor: 10,4. 

  

  1. Mueller SH, Lai AG,ValkovskayaM, Michailidou K, Bolla MK, Wang Q, Geisler J, et al. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry. Genome Med. 2023;15(1):18. Journal Impact Factor: 10,4.  

  

  1. Dong Y,ZhuangXX, Wang YT, Tan J, Feng D, Li M, Fang EF, et al. Chemical mitophagy modulators: Drug development strategies and novel regulatory mechanisms. Pharmacol Res. 2023;194:106835. Journal Impact Factor: 9,1.  

  

  1. Brun MK,BjorlykkeKH, Viken MK, Stenvik GE, Klaasen RA, Gehin JE, et al. HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases. J Intern Med. 2023;293(5):648-55. Journal Impact Factor: 9,0.  

  

  1. Riis RN, Riis MH, Benth JS,Augestad KM.Beyond the transanal total mesorectal excision moratorium: local and distant recurrence among patients operated for low rectal tumours-5-year follow-up from a Norwegian University Hospital. Br J Surg. 2023;110(11):1547-8. Journal Impact Factor: 8,6.  

  

  1. GreijdanusNG,Wienholts K, Ubels S, Talboom K, Hannink G, Wolthuis A, Riis R, et al. Stoma-free survival after anastomotic leak following rectal cancer resection: worldwide cohort of 2470 patients. Br J Surg. 2023;110(12):1863-76. Journal Impact Factor: 8,6. 

  

  1. Slevin F,ZattoniF, Checcucci E, Cumberbatch MGK, Nacchia A, Cornford P, Oldenburg, J, et al. A Systematic Review of the Efficacy and Toxicity of Brachytherapy Boost Combined with External Beam Radiotherapy for Nonmetastatic Prostate Cancer. Eur Urol Oncol. 2023;26:26. Journal Impact Factor: 8,3.  

  

  1. Lia K, R.K. Jørgensen R, Wold BL, Fluge Ø, Fagerli UM, Bersvendsen HS,Bhargava S,et al. Overall survival and causes of death in elderly patients with Hodgkin lymphoma: a Norwegian population-based case-control study. Haematologica. 2023;109(5):1403-12. Journal Impact Factor: 8,2. 

  

  1. Isaksen KT, Galleberg R,Mastroianni MA,Rinde M, Rusten LS, Barzenje D, et al. The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy. Haematologica. 2023;108(9):2454-66. Journal Impact Factor: 8,2.  

  

  1. Suzuki T, Kilbey A, Casa-Rodriguez N, Lawlor A, Georgakopoulou A, Hayman H,Kersten C,et al. beta-Catenin Drives Butyrophilin-like Molecule Loss and gammadelta T-cell Exclusion in Colon Cancer. Cancer Immunol Res. 2023;11(8):1137-55. Journal Impact Factor: 8,1.  

  

  1. MorraA,Mavaddat N, Muranen TA, Ahearn TU, Allen J, Andrulis IL, Geisler J, et al. The impact of coding germline variants on contralateral breast cancer risk and survival. Am J Hum Genet. 2023;110(3):475-86. Journal Impact Factor: 8,1.  

  

  1. Pun FW, Leung GHD, Leung HW,Rice J,Schmauck-Medina T, Lautrup S, Fang EF, et al. A comprehensive AI-driven analysis of large-scale omic datasets reveals novel dual-purpose targets for the treatment of cancer and aging. Aging Cell. 2023;22(12):e14017. Journal Impact Factor: 8,0.  

  

  1. Bergquist A,WeismullerTJ, Levy C, Rupp C, Joshi D, Nayagam JS, Jørgensen KK, et al. Impact on follow-up strategies in patients with primary sclerosing cholangitis. Liver Int. 2023;43(1):127-38. Journal Impact Factor: 6,0.  

  

  1. Moss TT, Stavem K, Aandahl A,GloersenAS, Gronberg BH, Neumann K,....., Lindquist, Case Report: Limbic encephalitis following treatment with durvalumab for small-cell lung cancer. Front. 2023;14:1278761. Journal Impact Factor: 5,7.  

  

  1. Kostner AH,Fuglestad AJ, Georgsen JB, Nielsen PS, Christensen KB, Zibrandtsen H,...., Kersten C. Fueling the flames of colon cancer - does CRP play a direct pro-inflammatory role? Front. 2023;14:1170443. Journal Impact Factor: 5,7.  

  

  1. CarmKT, Johannessen B, Bogaard M, Bakken AC,Maltau AV, Hoff AM, Axrona K, et al. Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer. Int J Cancer. 2023;152(5):945-51. Journal Impact Factor: 5,7.  

  

  1. Yndestad S,EngebrethsenC, Herencia-Ropero A, Nikolaienko O, Vintermyr OK, Lillestol RK, Geisler J, et al. Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer. JCO precis. 2023;7:e2300338. Journal Impact Factor: 5,3. 

  

  1. Hussaini P,Larsen TL,Ghanima W, Dahm AEA. Risk Factors for Bleeding in Cancer Patients Treated with Conventional Dose Followed by Low-Dose Apixaban for Venous Thromboembolism. Thrombosis and Haemostasis. 2023;124(4):351-62. Journal Impact Factor: 5,0.  

  

  

  1. Buckley CE, Yin X,Meltzer S, Ree AH, Redalen KR, Brennan L, et al.Energy Metabolism Is Altered in Radioresistant Rectal Cancer. Int. 2023;24(8):11. Journal Impact Factor: 4,9.  

  

  1. Pang N, Hu Q, Zhou Y, Xiao Y, Li W, Ding Y,Fang EF,et al. Nicotinamide Adenine Dinucleotide Precursor Suppresses Hepatocellular Cancer Progression in Mice. Nutrients. 2023;15(6):17. Journal Impact Factor: 4,8.  

  

  1. Lee GA,AktaaS, Baker E, Gale CP, Yaseen IF, Gulati G, et al. European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment. European Heart Journal - Quality of Care and Clinical Outcomes. 2023;9(1):1-7. Journal Impact Factor: 4,8.  

  

  1. Orstad S,FlottenO, Madebo T, Gulbrandsen P, Strand R, Lindemark F, et al. "The challenge is the complexity" - A qualitative study about decision-making in advanced lung cancer treatment. Lung Cancer. 2023;183:107312. Journal Impact Factor: 4,5.  

  

  1. Figlioli G, Billaud A, Wang Q, Bolla MK, Dennis J, Lush M,Geisler J,et al. Spectrum and Frequency of Germline FANCM Protein-Truncating Variants in 44,803 European Female Breast Cancer Cases. Cancers (Basel). 2023;15(13):23. Journal Impact Factor: 4,5. 

  

  1. Lindemann K,HeimisdottirDanbolt S, Ramberg L, Eyjolfsdottir B, Wang YY, Heli-Haugestol AG, et al. Patient-reported nausea after implementation of an enhanced recovery after surgery protocol for gynae-oncology patients. Int J Gynecol Cancer. 2023;33(8):1287-94. Journal Impact Factor: 4,1.  

  

  1. Bogaard M,SkotheimRI, Maltau AV, Kidd SG, Lothe RA, Axcrona K, et al. 'High proliferative cribriform prostate cancer' defines a patient subgroup with an inferior prognosis. Histopathology. 2023;83(6):853-69. Journal Impact Factor: 3,9.  

  

  1. Touma J, Pantalone MR, Rahbar A, Liu Y,VetvikK, Sauer T,...., Geisler J, Human Cytomegalovirus Protein Expression Is Correlated with Shorter Overall Survival in Breast Cancer Patients: A Cohort Study. Viruses. 2023;15(3):11. Journal Impact Factor: 3,8. 

  

  1. SenthakumaranT,Moen AEF, Tannaes TM, Endres A, Brackmann SA, Rounge TB, et al. Microbial dynamics with CRC progression: a study of the mucosal microbiota at multiple sites in cancers, adenomatous polyps, and healthy controls. Eur J Clin Microbiol Infect Dis. 2023;42(3):305-22. Journal Impact Factor: 3,7.  

  

  1. Larsen TL,SvalastogaM, Brekke J, Enden T, Froen H, Garresori H,..., Dahm AEA, Arterial events in cancer patients treated with apixaban for venous thrombosis. Thromb Res. 2023;228:128-33. Journal Impact Factor: 3,7.  

  

  1. Figlioli G, Billaud A, Ahearn TU,AntonenkovaNN, Becher H, Beckmann MW, Geisler J, et al. FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women. European Journal of Human Genetics. 2023;31(5):578-87. Journal Impact Factor: 3,7.  

  

  1. Sleiman A, Lalanne K, Vianna F, Perrot Y, Richaud M,SenGuptaT, Nilsen H, et al. Targeted Central Nervous System Irradiation with Proton Microbeam Induces Mitochondrial Changes in Caenorhabditis elegans. Biology (Basel). 2023;12(6):09. Journal Impact Factor: 3,6.  

  

  1. Levi H, Carmi S, Rosset S, Yerushalmi R, Zick A, Yablonski-Peretz T,Geisler J,et al. Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel. J Med Genet. 2023;60(12):1186-97. Journal Impact Factor: 3,5.  

  

  1. CestelliL,Gulsvik A, Johannessen A, Stavem K, Nielsen R. Reduced lung function and cause-specific mortality: A population-based study of Norwegian men followed for 26 years. Respir Med. 2023;219:107421. Journal Impact Factor: 3,5.  

  

  1. Bucher-Johannessen C, Birkeland EE, Vinberg E,BemanianV, Hoff G, Berstad P, et al. Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing. Front. 2023;13:1183039. Journal Impact Factor: 3,5.  

  

  1. BjornetroT, Bousquet PA, Redalen KR,Troseid AS, Luders T, Stang E,...., Ree AH, Next-generation sequencing reveals mitogenome diversity in plasma extracellular vesicles from colorectal cancer patients. BMC Cancer. 2023;23(1):650. Journal Impact Factor: 3,4.  

  

  1. Bakke KM, Meltzer S, Grovik E, Negard A, Holmedal SH, Mikalsen LTG, et al. Imaging the tumour microenvironment in rectal cancer: Decline in tumour blood flow during radiotherapy predicts good outcome. Phys Imaging Radiat Oncol. 2023;25:100417. Journal Impact Factor: 3,4.  

  

  1. Wang F,GiskeodegardGF, Skarra S, Engstrom MJ, Hagen L, Geisler J, et al. Association of serum cortisol and cortisone levels and risk of recurrence after endocrine treatment in breast cancer. Clin Exp Med. 2023;23(7):3883-93. Journal Impact Factor: 3,2.  

  

  1. Teig CJP, Bond MJ, Grotle M,KjollesdalM, Saga S, Cvancarova MS, et al. A novel method for the translation and cross-cultural adaptation of health-related quality of life patient-reported outcome measurements. Health Qual Life Outcomes. 2023;21(1):13. Journal Impact Factor: 3,2. 

  

  1. ChaiQ,Yang Z, Liu X, An D, Du J, Ma X, Rand K, et al. Valuation of EQ-5D-5L health states from cancer patients' perspective: a feasibility study. Eur J Health Econ. 2023;14:14. Journal Impact Factor: 3,1. 

  

  1. SchandizH, Park D, Kaiser YL,Lyngra M, Talleraas IS, Geisler J, ....., Sauer, Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact. Breast Cancer Res Treat. 2023;201(2):329-38. Journal Impact Factor: 3,0.   

 

  1. Eriksen GF,BenthJS, Gronberg BH, Rostoft S, Kirkhus L, Kirkevold O, et al. Geriatric impairments are associated with reduced quality of life and physical function in older patients with cancer receiving radiotherapy - A prospective observational study. J Geriatr Oncol. 2023;14(1):101379. Journal Impact Factor: 3,0. 

  

  1. Bhargava S,BotteriE, Berthelsen M, Iqbal N, Randel KR, Holme O, et al. Lower participation among immigrants in colorectal cancer screening in Norway. Front. 2023;11:1254905. Journal Impact Factor: 3,0. 

  

  1. RoysetIM, Eriksen GF,Benth JS, Saltvedt I, Gronberg BH, Rostoft S, et al. Edmonton Frail Scale predicts mortality in older patients with cancer undergoing radiotherapy-A prospective observational study. PLoS ONE. 2023;18(3):e0283507. Journal Impact Factor: 2,9.  

  

  1. Pieterse AH,Gulbrandsen P, Ofstad EH,Menichetti J. What does shared decision making ask from doctors? Uncovering suppressed qualities that could improve person-centered care. Patient Educ Couns. 2023;114:7. Journal Impact Factor: 2,9. 

  

  1. Morra A, Schreurs MAC, Andrulis IL, Anton-Culver H, Augustinsson A, Beckmann MW,Geisler J,et al. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. Cancer Med. 2023;12(15):16142-62. Journal Impact Factor: 2,9.  

  

  1. Gravdahl E, Steine S, Augestad KM,Fredheim OM.Use and safety of peripherally inserted central catheters and midline catheters in palliative care cancer patients: a retrospective review. Support Care Cancer. 2023;31(10):580. Journal Impact Factor: 2,8.  

  

  1. Bohn S,OldervollLM, Reinertsen KV, Seland M, Fossa A, Kiserud C, Wisløff T, et al. The feasibility of a multidimensional intervention in lymphoma survivors with chronic fatigue. Support Care Cancer. 2023;32(1):22. Journal Impact Factor: 2,8.  

  

  1. Stavnes K,Ruud T,Benth JS, Hanssen-Bauer K, Solantaus T, Hilsen M,..., Weidmand. Norwegian health personnel's contacts and referrals for children of ill parents: an exploratory cross-sectional multi-centre study. BMC Health Serv Res. 2023;23(1):13. Journal Impact Factor: 2,7.  

  

  1. GjersetGM,Kiserud CE, Wisloff T, McCarthy JB, Thorsen L. Perceived burden and need for support among caregivers of cancer patients. Acta Oncol. 2023;62(7):794-802. Journal Impact Factor: 2,7.  

  

  1. Geisler J,KarihtalaP, Tuxen M, Valachis A, Holm B. Current treatment landscape of HR+/HER2- advanced breast cancer in the Nordics: a modified Delphi study. Acta Oncol. 2023;62(12):1680-8. Journal Impact Factor: 2,7.  

  

  1. GachabayovM, Bergamaschi R, Wasmuth H,Faerden A, Javadov M, Cianchi F, et al. Oncological monitoring after transanal total mesorectal excision for rectal neoplasia. Tech Coloproctol. 2023;27(12):1411-2. Journal Impact Factor: 2,7.  

  

  1. Nystad W, Hjellvik V, Larsen IK, Robsahm TE, Sund ER, Krokstad S,WisloffT, et al. National health registries - a 'goldmine' for studying non-communicable disease occurrence in Norway - the NCDNOR project. Scand J Public Health. 2023:14034948231214580. Journal Impact Factor: 2,6.  

  

  1. Njor SH,HeinävaaraS, Stefansdóttir H, Nygård M, Guomundsdóttir EM, Bhargava S, et al. Differences in mammography screening attendance among non-Western immigrants in Denmark, Finland, Iceland and Norway. Prev Med Rep. 2023;36:7. Journal Impact Factor: 2,4.  

  

  1. Augestad KM,SkyrudKD, Lindahl AK, Helgeland J. Hospital variations in failure to rescue after abdominal surgery: a nationwide, retrospective observational study. BMJ Open. 2023;13(11):e075018. Journal Impact Factor: 2,4.  

  

  1. Quan X, Xin Y,Wang HL, Sun Y, Chen C, Zhang J. Implications of altered sirtuins in metabolic regulation and oral cancer.Peerj. 2023;11:e14752. Journal Impact Factor: 2,3. 

  

  1. Johansen ML, Eriksrud O, Thorkildsen J, Norum OJ,WisloffT, Taksdal I, et al. Muscle strength characteristics following megaprosthetic knee reconstruction for bone sarcoma. Surg Oncol. 2023;48:101944. Journal Impact Factor: 2,3. 

  

  1. Nygaard V,Ree AH,Dagenborg VJ, Borresen-Dale AL, Edwin B, Fretland AA, et al. A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases. Cancer Res Commun. 2023;3(2):235-44. Journal Impact Factor: 2,0.  

  

  1. Kleven AG,MiaskowskiC, Torstveit AH, Ritchie CS, Engh ME, Andersen E, et al. Quality of life of older gynecologic oncology patients at the initiation of chemotherapy. Nurs. 2023;10(10):6749-57. Journal Impact Factor: 2,0.  

  

  1. Fredheim OM,MaterstvedtLJ, Skulberg I, Magelssen M. Ought the level of sedation to be reduced during deep palliative sedation? A clinical and ethical analysis. BMJ Support Palliat Care. 2023;13(E3):e984-e9. Journal Impact Factor: 2,0.  

  

  1. Borgbjerg J,Thompson JD, Salte IM,Frokjaer JB. Towards AI-augmented radiology education: a web-based application for perception training in chest X-ray nodule detection. Br J Radiol. 2023;96(1152):20230299. Journal Impact Factor: 1,8.  

  

  1. SofizadehN,Bjerkehagen B, Solheim T, Sapkota D, Soland TM. The spectrum and frequency of histopathological diagnosis of oral diseases in Oslo: Implications to oral pathology syllabus. Eur J Dent Educ. 2023;27(2):325-31. Journal Impact Factor: 1,7.  

  

  1. Aas K, Sherif A. Long-term patient follow-up should be routinely implemented in radiotherapy units to detect late adverse effects after cancer treatment. Scand J Urol.2023;58:30-1.Journal Impact Factor: 1,4.  

  

  1. VrielinkH, Le Poole K,Stegmayr B, Kielstein J, Berlin G, Ilhan O, Aandahl, et al. The world apheresis association registry, 2023 update. Transfusion and Apheresis Science. 2023;62(6) (no pagination). Journal Impact Factor: 1,4.  

  

  1. OtrebskiNilsson M,Aas K, Myklebust TA, Gjelsvik YM, Haug ES, Fossa SD, et al. Do all prostate cancer patients want, and experience shared decision making prior to curative treatment? Scand J Urol. 2023;58:133-40. Journal Impact Factor: 1,4.  

  

  1. Nilsen TS,SaeterM, Sarvari SI, Reinertsen KV, Johansen SH, Edvardsen ER, Wisloff T, et al. Effects of Aerobic Exercise on Cardiorespiratory Fitness, Cardiovascular Risk Factors, and Patient-Reported Outcomes in Long-Term Breast Cancer Survivors: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2023;12:e45244. Journal Impact Factor: 1,4. 

  

  1. Karttunen E,HervonenP, Hosseini Aliabad A, Oldenburg J, Pappot H, Sairanen J, et al. Incidence, mortality and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic countries between 1990 and 2019. Scand J Urol. 2023;57(1-6):15-21. Journal Impact Factor: 1,4.  

  

  1. Storlien T,Dahm AEA.[Treatment of older patients with acute myelogenous leukaemia without allogenic stem cell transplantation at Akershus University Hospital]. Tidsskr Nor Laegeforen. 2023;143(15):24. Journal Impact Factor: 1,2.  

  

  1. Larsen TL, Ghanima W,SandsetPM, Froen H, Jacobsen EM, Torfoss D, ....., Dahm AEA,  [Factor Xa inhibitors in the prevention and treatment of venous thromboembolism in cancer patients]. Tidsskr Nor Laegeforen. 2023;142(1):17. Journal Impact Factor: 1,2.  

  

  1. Berg J,TonevGT, Grimnes JO, Suhrke P, Hammarstrom C, Vu HPN. Thymoma with pleural metastases. Tidsskr Nor Laegeforen. 2023;143(9):13. Journal Impact Factor: 1,2.  

  

  1. Borgbjerg J, Larsen NE, Salte IM, Gronli NR,KlaestrupE, Negard A. Dataset on renal tumor diameter assessment by multiple observers in normal-dose and low-dose CT. Data Brief. 2023;51:109672. Journal Impact Factor: 1,0.  

  

  1. Levy-Jurgenson A,TekpliX, Kristensen VN, Yakhini Z. Analysis of Spatial Molecular Data. Methods Mol Biol. 2023;2614:349-56. Journal Impact Factor: 0.98   

  1. Oldenburg J, Berney DM, Bokemeyer C, Climent MA, Daugaard G, Gietema JA, et al. Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(4):362-75. Journal Impact Factor: 56,7. 

  

  1. Kater AP, Levin MD, Dubois J, Kersting S, Enggaard L, Veldhuis GJ,Tran HTTet al. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial. Lancet Oncol. 2022;23(6):818-28. Journal Impact Factor: 41,6. 

  

  1. MavaddatN, Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Keeman R,Geisler J, et al. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncol. 2022;8(3):e216744. Journal Impact Factor: 22,3. 

  

  1. LirussiL, Ayyildiz D, Liu Y, Montaldo NP, Carracedo S, Aure MR,Touma J, Kristensen VN, Geiselr J, Nilsen H. A regulatory network comprising let-7 miRNA and SMUG1 is associated with good prognosis in ER+ breast tumours. Nucleic Acids Res. 2022;50(18):10449-68. Journal Impact Factor: 16,7. 

  

  1. Williams SA, Ostroff R,HinterbergMA, Coresh J, Ballantyne CM, Matsushita K, Omland T et al. A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk. Sci Transl Med. 2022;14(639):eabj9625. Journal Impact Factor: 15,8. 

  

  1. Tian Y, Wang W, Lautrup S, Zhao H, Li X, Law PWN,Fang EFet al. WRN promotes bone development and growth by unwinding SHOX-G-quadruplexes via its helicase activity in Werner Syndrome. Nat Commun. 2022;13(1) (no pagination). Journal Impact Factor: 14,7. 

  

  1. Omland T, Heck SL, Gulati G. The Role ofCardioprotectionin Cancer Therapy Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2022;4(1):19-37. Journal Impact Factor: 13,6. 

  

  1. DomanskaD, Majid U, Karlsen VT,Merok MA, Beitnes AR, Yaqub S, et al. Single-cell transcriptomic analysis of human colonic macrophages reveals niche-specific subsets. J Exp Med. 2022;219(3):09. Journal Impact Factor: 12,8. 

  

  1. Hoye E,DagenborgVJ, Torgunrud A, Lund-Andersen C, Fretland AA, Lorenz S, Ree AH, et al. T cell receptor repertoire sequencing reveals chemotherapy-driven clonal expansion in colorectal liver metastases. Gigascience. 2022;12(12):28. Journal Impact Factor: 11,8. 

  

  1. Syversen SW,JyssumI, Tveter AT, Tran TT, Sexton J, Provan SA, Ricanek P, Jahnsen J, Jørgensen KK, et al. Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy. Arthritis rheumatol. 2022;74(8):1321-32. Journal Impact Factor: 11,4. 

  

  1. Venizelos A,EngebrethsenC, Deng W, Geisler J, Geisler S, Iversen GT, et al. Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy. Genome Med. 2022;14(1):86. Journal Impact Factor: 10,4. 

  

  1. Dorling L, Carvalho S, Allen J, Parsons MT, Fortuno C, González-Neira A,Geisler J,et al. Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Med. 2022;14(1):17. Journal Impact Factor: 10,4. 

  

  1. Ellingsen EB,Aamdal E, Guren T, Lilleby W, Brunsvig PF, Mangsbo SM, et al. Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials. J Immunother Cancer. 2022;10(5):05. Journal Impact Factor: 10,3. 

  

  1. ForsseD, Barbero ML, Werner HMJ,Woie K, Nordskar N, Berge Nilsen E, Engh ME, et al. Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: a prospective cohort study. Am J Obstet Gynecol. 2022;226(1):90.e1-.e20. Journal Impact Factor: 9,7. 

  

  1. Brun MK, Goll GL,Jorgensen KK, Sexton J, Gehin JE, Sandanger O,Mørk C, Jahnsen J et al. Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial. J Intern Med. 2022;292(3):477-91. Journal Impact Factor: 9,0. 

  

  1. BjornelvGMW,Zolic-Karlsson Z, Dueland S, Line PD, Aas E. Cost-effectiveness of liver transplantation versus last-resort systemic therapy for colorectal liver metastases. Br J Surg. 2022;109(6):483-5. Journal Impact Factor: 8,7. 

  

  1. Andersen BT, Kazaryan AM,StimecBV, Edwin B, Rancinger P, Ignjatovic D. Personalized surgery for the splenic flexure cancer: new frontiers. Br J Surg. 2022;109(9):880-1. Journal Impact Factor: 8,7. 

  

  1. Smeland K, Holte H, Fagerli UM,BersvendsenH, Hjermstad MJ, Loge JH, Linnsund MD et al. Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplant and its effect on health-related quality of life. Haematologica. 2022;107(11):2698-707. Journal Impact Factor: 8,2. 

  

  1. Dobson R, Du PY, Raso-Barnett L, Yao WQ, Chen Z, Casa C,Farkas Let al. Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis. Haematologica. 2022;107(2):489-99. Journal Impact Factor: 8,2. 

  

  1. AamdalE, Skovlund E, Jacobsen KD, Straume O,Kersten C, Herlofsen O, et al. Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment. ESMO open. 2022;7(5):100588. Journal Impact Factor: 7,1. 

  

  1. Christensen IE,JyssumI, Tveter AT, Sexton J, Tran TT, Mjaaland S, Jahnsen J et al. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study. BMC Med. 2022;20(1):378. Journal Impact Factor: 7,1. 

  

  1. Aasbo G, Trope A, Nygard M,Christiansen IK,Baasland I, Iversen GA, et al. HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial. Br J Cancer. 2022;127(10):1816-26. Journal Impact Factor: 6,4. 

  

  1. Meltzer S,NegardA, Bakke KM, Hamre HM, Kersten C, Hofsli E, et al. Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer. Br J Cancer. 2022;127(12):2227-33. Journal Impact Factor: 6,4. 

  

  1. FontugneJ, Cai PY, Alnajar H, Bhinder B, Park K, Ye H,Axcrona K et al. Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci. JCI insight. 2022;7(4):22. Journal Impact Factor: 6,3. 

  

  1. Helland A,RussnesHG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Hamre H, Ree AH et al. Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. J. 2022;20(1):225. Journal Impact Factor: 6,1. 

  

  1. Ahearn TU, Zhang H, Michailidou K, Milne RL, Bolla MK, Dennis J,Geisler Jet al. Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research. 2022;24(1) (no pagination). Journal Impact Factor: 6,1. 

  

  1. Tahiri A, Puco K, Naji F,Kristensen VN, Alfsen GC,Farkas L, et al. Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors. Oncotarget. 2022;13:970-81. Journal Impact Factor: 5,168 (2016 JIF). 

  

  1. AamdalE,Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, et al. Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up. Int J Cancer. 2022;150(1):100-11. Journal Impact Factor: 5,7. 

  

  1. Larsen TL,Garresori H, Brekke J, Enden T, Froen H, Jacobsen EM,..., Ree AH, ...,Dahm AE. Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up. J Thromb Haemost. 2022;20(5):1166-81. Journal Impact Factor: 5,5. 

  

  1. Ambrosini M, Del Re M, Manca P,Hendifar A, Drilon A, Harada G, Ree AH, et al.ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series. JCO precis. 2022;6:e2200015. Journal Impact Factor: 5,3. 

  

  1. Dennis J, Tyrer JP, Walker LC, Michailidou K, Dorling L,Kristensen VN, et al.Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology. 2022;5:1-15. Journal Impact Factor: 5,2. 

  

  1. Bjørklund S, Aure MR, Häkkinen J, Vallon-Christersson J, Kumar S, Bull EvensenK,...,Kristensen VN, Subtype and cell type specific expression of lncRNAs provide insight into breast cancer. Communications Biology. 2022;5(1):1-14. Journal Impact Factor: 5,2. 

  

  1. Syversen SW,Jyssum I, Tveter AT, Sexton J, Christensen IE, Tran TT,..., Jahnsen, J,..., Jørgensen KK, Goll GL, Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy. RMD Open. 2022;8(2) (no pagination). Journal Impact Factor: 5,1. 

  

  1. Riise J, Meyer S,BlaasI, Chopra A, Tran TT, Delic-Sarac M, Hestdalen ML, Brodin E, Rustad EH, et al. Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination. Br J Haematol. 2022;197(6):697-708. Journal Impact Factor: 5,1. 

  

  1. Kidd SG, Bogaard M,CarmKT, Bakken AC, Maltau AMV, Lovf M, Axcrona K, et al. In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis. Mol Oncol. 2022;16(15):2810-22. Journal Impact Factor: 5,0. 

  

  1. Bertelsen BE, Viste K, Helland T, Hagland M,SoilandH, Geisler J, et al. Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients. J Clin Endocrinol Metab. 2022;107(5):1368-74. Journal Impact Factor: 5,0. 

  

  1. Nilsen TS, Johansen SH, Thorsen L, Fairman CM,WisloffT, Raastad T. Does Androgen Deprivation for Prostate Cancer Affect Normal Adaptation to Resistance Exercise? Int J Environ Res Public Health. 2022;19(7):23. Journal Impact Factor: 4,614 (2021 JIF). 

  

  1. Lee GA,Aktaa S, Baker E, Gale CP, Yaseen IF, Gulati G, et al. European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment. Eur Heart J Qual Care Clin Outcomes. 2022;9(1):1-7. Journal Impact Factor: 4,9. 

  

  1. DeLaereB, Crippa A, Discacciati A, Larsson B, Oldenburg J, Mortezavi A, et al. Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer. Eur Urol Focus. 2022;8(6):1617-21. Journal Impact Factor: 4,9. 

  

  1. Bjerknes C,FramrozeB, Currie C, Pettersen CHH, Axcrona K, Hermansen E. Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis. Mar. 2022;20(4):28. Journal Impact Factor: 4,9. 

  

  1. StrommeJM, Johannessen B,Kidd SG, Bogaard M, Carm KT, Zhang X, Axcrona, K. et al. Expressed prognostic biomarkers for primary prostate cancer independent of multifocality and transcriptome heterogeneity. Cancer Gene Ther. 2022;29(8-9):1276-84. Journal Impact Factor: 4,8. 

  

  1. LovestadAH,Repesa A, Costanzi JM, Lagstrom S, Christiansen IK, Rounge TB, et al. Differences in integration frequencies and APOBEC3 profiles of five high-risk HPV types adheres to phylogeny. Tumour Virus Res. 2022;14:200247. Journal Impact Factor: 4,7. 

  

  1. Caglar Cil O, Metin OK,CayirA. Evaluation of Mitochondrial Copy Number in Thyroid Disorders. Arch Med Res. 2022;53(7):711-7. Journal Impact Factor: 4,7. 

  

  1. Farooq A, Troen G,DelabieJ, Wang J. Integrating whole genome sequencing, methylation, gene expression, topological associated domain information in regulatory mutation prediction: A study of follicular lymphoma. Comput Struct Biotechnol J. 2022;20:1726-42. Journal Impact Factor: 4,5. 

  

  1. Nygard M,EngesaeterB, Castle PE, Berland JM, Eide ML, Iversen OE, Christiansen IK, et al. Randomized Implementation of a Primary Human Papillomavirus Testing-based Cervical Cancer Screening Protocol for Women 34 to 69 Years in Norway. Cancer Epidemiol Biomarkers Prev. 2022;31(9):1812-22. Journal Impact Factor: 3,7. 

  

  1. Seland M, Skrede K, Lindemann K,Skaali T, Blomhoff R, Bruheim K, Wisloff T, et al. Distress, problems and unmet rehabilitation needs after treatment for gynecological cancer. Acta Obstet Gynecol Scand. 2022;101(3):313-22. Journal Impact Factor: 3,5. 

  

  1. Ellingsen CL,Alfsen GC, Ebbing M, Pedersen AG, Sulo G, Vollset SE, et al. Garbage codes in the Norwegian Cause of Death Registry 1996-2019. BMC Public Health. 2022;22(1):1301. Journal Impact Factor: 3,5. 

  

  1. Sahakyan MA, Verbeke CS,TholfsenT, Ignjatovic D, Kleive D, Buanes T, et al. Prognostic Impact of Resection Margin Status in Distal Pancreatectomy for Ductal Adenocarcinoma. Ann Surg Oncol. 2022;29(1):366-75. Journal Impact Factor: 3,4. 

  

  1. Reis J, Boavida J, Tran HT,LyngraM, Reitsma LC, Schandiz H, Geisler J, et al. Assessment of preoperative axillary nodal disease burden: breast MRI in locally advanced breast cancer before, during and after neoadjuvant endocrine therapy. BMC Cancer. 2022;22(1):702. Journal Impact Factor: 3,4. 

  

  1. Nymo LS, Myklebust TA,Hamre H, Moller B, Lassen K.Treatment and survival of patients with pancreatic ductal adenocarcinoma: 15-year national cohort. BJS open. 2022;6(2):08. Journal Impact Factor: 3,4. 

  

  1. Knuth F,GroendahlAR, Winter RM, Torheim T, Negard A, Holmedal SH, Bakke KM, Meltzer S, et al. Semi-automatic tumor segmentation of rectal cancer based on functional magnetic resonance imaging. Phys Imaging Radiat Oncol. 2022;22:77-84. Journal Impact Factor: 3,4. 

  

  1. Astrup GL, Rohde G, Rimehaug SA, Andersen MH, Bernklev T, Bjordal K,Stavem K, et al. Comparing the use of patient-reported outcomes in clinical studies in Europe in 2008 and 2018: a literature review. Qual Life Res. 2022;31(3):659-69. Journal Impact Factor: 3,3. 

  

  1. Kaufmann E, Antonelli L, Albers P, Cary C,Gillessen Sommer S, Heidenreich A, Oing C, Oldenburg J, et al. Oncological Follow-up Strategies for Testicular Germ Cell Tumours: A Narrative Review. Eur Urol Open Sci. 2022;44:142-9. Journal Impact Factor: 3,2. 

  

  1. BarcelliniA,Dominoni M, Dal Mas F, Biancuzzi H, Venturini SC, Gardella B, Orlandi E, Bø K, Sexual Health Dysfunction After Radiotherapy for Gynecological Cancer: Role of Physical Rehabilitation Including Pelvic Floor Muscle Training. Frontiers in Medicine. 2022;8(no pagination). Journal Impact Factor: 3,1. 

  

  1. StimecBV,Ignjatovic D. Visible Lymph Affluents in the D3 Volume: An MDCTA Pictorial Essay. Diagnostics (Basel). 2022;12(10):09. Journal Impact Factor: 3,0. 

  

  1. RoysetI,Saltvedt I, Rostoft S, Gronberg BH, Kirkevold O, Oldervoll L,......, Benth JS. Geriatric assessment with management for older patients with cancer receiving radiotherapy. Protocol of a Norwegian cluster-randomised controlled pilot study. J Geriatr Oncol. 2022;13(3):363-73. Journal Impact Factor: 3,0. 

  

  1. StikbakkeE,Schirmer H, Knutsen T, Stoyten M, Wilsgaard T, Giovannucci EL, et al. Systolic and diastolic blood pressure, prostate cancer risk, treatment, and survival. The PROCA-life study. Cancer Med. 2022;11(4):1005-15. Journal Impact Factor: 2,9. 

  

  1. Skretting IK,Ruud EA, Ashraf H.Diagnostic yield, complications, pathology and anatomical features in CT-guided percutaneous needle biopsy of mediastinal tumours. PLoS ONE. 2022;17(11):e0277200. Journal Impact Factor: 2,9. 

  

  1. MalengeMM,Maaland AF, Repetto-Llamazares A, Middleton B, Nijland M, Visser L, Ree AH, et al. Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro. PLoS ONE. 2022;17(4):e0267543. Journal Impact Factor: 2,9. 

  

  1. Larsen BH,Lundeby T, Gulbrandsen P, Forde R,Gerwing J. Physicians' responses to advanced cancer patients' existential concerns: A video-based analysis. Patient Educ Couns. 2022;105(10):3062-70. Journal Impact Factor: 2,9. 

  

  1. Larsen BH,Lundeby T,Gerwing J, Gulbrandsen P, Forde R. "Eh - What type of cells are these - flourishing in the liver?" Cancer patients' disclosure of existential concerns in routine hospital consultations. Patient Educ Couns. 2022;105(7):2019-26. Journal Impact Factor: 2,9. 

  

  1. Torstveit AH,MiaskowskiC, Loyland B, Grov EK, Ritchie CS, Paul SM, Ellstrom Engh AM, et al. Characteristics associated with decrements in objective measures of physical function in older patients with cancer during chemotherapy. Support Care Cancer. 2022;30(12):10031-41. Journal Impact Factor: 2,8. 

  

  1. Eriksen GF,SaltyteBenth J, Gronberg BH, Rostoft S, Kirkevold O, Bergh S, et al. Cognitive Trajectories in Older Patients with Cancer Undergoing Radiotherapy-A Prospective Observational Study. Curr. 2022;29(7):5164-78. Journal Impact Factor: 2,8. 

  

  1. Bousquet PA, Meltzer S, Fuglestad AJ, Luders T,Esbensen Y, Juul HV, et al. The mitochondrial DNA constitution shaping T-cell immunity in patients with rectal cancer athigh risk of metastatic progression. Clin Transl Oncol. 2022;24(6):1157-67. Journal Impact Factor: 2,8. 

  

  1. Borza T, Harneshaug M, Kirkhus L, Saltyte Benth J, Selbaek G, Bergh S, et al. The course of depressive symptoms and mortality in older patients with cancer. Aging Ment Health. 2022;26(6):1153-60. Journal Impact Factor: 2,8. 

  

  1. Ree AH,MaelandsmoGM, Flatmark K, Russnes HG, Gomez Castaneda M, Aas E. Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study. Acta Oncol. 2022;61(8):955-62. Journal Impact Factor: 2,7. 

  

  1. Knuth F, Adde IA, Huynh BN,GroendahlAR, Winter RM, Negard A, Meltzer S, Ree AH, et al. MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts. Acta Oncol. 2022;61(2):255-63. Journal Impact Factor: 2,7. 

  

  1. Fuglestad AJ, Meltzer S, Ree AH,McMillan DC, Park JH,Kersten C. The clinical value of C-reactive protein and its association with tumour location in patients undergoing curative surgery for colorectal cancer - a ScotScan collaborative study. Acta Oncol. 2022;61(10):1248-55. Journal Impact Factor: 2,7. 

  

  1. Eriksen GF,Saltyte Benth J, Gronberg BH, Rostoft S, Kirkhus L, Kirkevold O, et al. Geriatric impairments are prevalent and predictive of survival in older patients with cancer receiving radiotherapy: a prospective observational study. Acta Oncol. 2022;61(4):393-402. Journal Impact Factor: 2,7. 

  

  1. Bhargava S,CzapkaE, Hofvind S, Kristiansen M, Diaz E, Berstad P. Polish immigrants' access to colorectal cancer screening in Norway - a qualitative study. BMC Health Serv Res. 2022;22(1):1332. Journal Impact Factor: 2,7. 

  

  1. Tryggestad AMA,AxcronaK, Axcrona U, Bigalke I, Brennhovd B, Inderberg EM, et al. Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy. Prostate. 2022;82(2):245-53. Journal Impact Factor: 2,6. 

  

  1. AlhaugOK, Kaur S, Dolatowski F,Småstuen MC, Solberg TK, Lonne G. Accuracy and agreement of national spine register data for 474 patients compared to corresponding electronic patient records. Eur Spine J. 2022;31(3):801-11. Journal Impact Factor: 2,6. 

  

  1. Sahakyan MA,RosokBI, Tholfsen T, Kleive D, Waage A, Ignjatovic D, et al. Implementation and training with laparoscopic distal pancreatectomy: 23-year experience from a high-volume center. Surg Endosc. 2022;36(1):468-79. Journal Impact Factor: 2,4. 

  

  1. Luzon JA,Thorsen Y, Nogueira LP, Andersen SN, Edwin B, Haugen HJ, Ignjatovic D et al. Reconstructing topography and extent of injury to the superior mesenteric artery plexus in right colectomy with extended D3 mesenterectomy: a composite multimodal 3-dimensional analysis. Surg Endosc. 2022;36(10):7607-18. Journal Impact Factor: 2,4. 

  

  1. Christiansen O, Kirkevold O, Bratt O,SaltyteBenth J, Slaaen M. Experience Measures after Radical Prostatectomy: A Register-Based Study Evaluating the Association between Patient-Reported Symptoms and Quality of Information. Healthcare (Basel). 2022;10(3):12. Journal Impact Factor: 2,4. 

  

  1. Andersen BT,StimecBV, Kazaryan AM, Rancinger P, Edwin B, Ignjatovic D. Re-interpreting mesenteric vascular anatomy on 3D virtual and/or physical models, part II: anatomy of relevance to surgeons operating splenic flexure cancer. Surg Endosc. 2022;36(12):9136-45. Journal Impact Factor: 2,4. 

  

  1. Andersen BT,StimecBV, Edwin B, Kazaryan AM, Maziarz PJ, Ignjatovic D. Re-interpreting mesenteric vascular anatomy on 3D virtual and/or physical models: positioning the middle colic artery bifurcation and its relevance to surgeons operating colon cancer. Surg Endosc. 2022;36(1):100-8. Journal Impact Factor: 2,4. 

  

  1. Banipal GS, Stimec BV, Andersen SN, Faerden AE, Edwin B, Baral J, Saltyte Benth J, Ignjatovic D. Comparing 5-Year Survival Rates Before and After Re-stratification of Stage I-III Right-Sided Colon Cancer Patients by Establishing the Presence/Absence of Occult Tumor Cells and Lymph Node Metastases in the Different Levels of Surgical Dissection. J Gastrointest Surg. 2022;26(10):2201-11. Journal Impact Factor: 2,2. 

  

  1. Bach-GansmoT,Korsan K, Bogsrud TV. Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer. Tomography. 2022;8(3):1477-84. Journal Impact Factor: 2,2. 

  

  1. StromsvikN, Olsson P,Gravdehaug B, Luras H, Schlichting E, Jorgensen K, et al. "It was an important part of my treatment": a qualitative study of Norwegian breast Cancer patients' experiences with mainstreamed genetic testing. Hered. 2022;20(1):6. Journal Impact Factor: 2,0. 

  

  1. van derWerffHFL, Michelet TH, Fredheim OM, Steine S. "Do not resuscitate" order and end-of-life treatment in a cohort of deceased in a Norwegian University Hospital. Acta Anaesthesiol Scand. 2022;66(8):1009-15. Journal Impact Factor: 1,9. 

  

  1. Sah VR, Karlsson J, Jespersen H, Lindberg MF, Nilsson LM, Ny L, et al. Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma. Melanoma Res. 2022;32(4):241-8. Journal Impact Factor: 1,5. 

  

  1. Christiansen O, Bratt O, Kirkevold O,Benth JS, Manoharan P, Selnes A, et al. Predictors of upgrading from low-grade cancer at prostatectomy in men withbiparametric magnetic resonance imaging. Cent. 2022;75(1):35-40. Journal Impact Factor: 1,4. 

  

  1. Gulati G, Tjessem KH,HorndalsveenH, Halvorsen S, Haakensen VD. [Checkpoint inhibitor-induced myocarditis]. Tidsskr Nor Laegeforen. 2022;142(18):13. Journal Impact Factor: 1,2. 

  

  1. Gjersvik P,Veierod MB, Thompson A, Grzyb K, Liland KH, Vazov N, et al. Histopathologic reassessment of melanoma and other melanocytic skin lesions excised in 2009 and 2018-2019. Tidsskr Nor Laegeforen. 2022;142(15):25. Journal Impact Factor: 1,2. 

  

  1. Moen TM,StimecB, Ignjatovic D. The Use of a Vascular Roadmap at Surgery Evens out Surgeons? Expectations on Operating Time, Blood Loss, Lymph Nodes Harvest and Operative Difficulty when Performing Right Colectomy with Extended D3 Mesenterectomy. Chirurgia. 2022;117(5):579-84. Journal Impact Factor: 0,8. 

  

  1. Blakstad H,Wohlleben C,Saxhaug C, Brandal P. SMART syndrome: two cases highlighting a complex and rare complication of brain irradiation. BMJ Case Rep. 2022;15(9):27. Journal Impact Factor: 0,6. 
Sist oppdatert 02.07.2026